

# Exhibit 2

EXHIBIT 3  
WIT: Gillegon-Kayphel  
DATE: 10-24-78  
C. Campbell, RDR CRR CSR #13921

## **NORCO**

### **IP**

2000-2015 – Watson Laboratories, Inc. now known as Actavis  
Laboratories Florida  
2016 – Allergan Sales, LLC  
2017 – Present Allergan Pharmaceuticals Limited (APIL)

### **MFS**

< July 2015 Watson Laboratories, Inc. (Nevada)  
> July 2015 Warner Chilcott Company, LLC (Puerto Rico)  
divested to Teva August 2016

### **Sales**

Prior Actavis Pharma, Inc. formerly known as Watson Pharma, Inc.  
current Allergan USA, Inc.

## **KADIAN**

### **IP**

12/08 – 13 – Actavis Elizabeth LLC  
2013 – 2016 – Actavis Laboratories Utah formerly known as Watson  
Laboratories Salt Lake  
2016 – Allergan Sales, LLC

### **MFS**

Actavis Elizabeth TPM to Alpharma since 12/19/2005  
Actavis Elizabeth acquired Product in December 2008  
Continues to supply Allergan USA, Inc.

### **Sales**

Previous Actavis Pharma, Inc. formerly known as Watson Pharma, Inc.  
Today Allergan USA, Inc.

NO	Topic	Response
43.1	The corporate structure of all Allergan entities (including Allergan Finance, LLC, Allergan plc, and all subsidiaries, parents, predecessors, successors and/or associated entities resulting from any and all mergers over the years) and each such entity's involvement with any opioid products from 1995 to the present, including the identification of all drugs, the entity's role in connection with such drugs, and all opioid management involved.	<p data-bbox="1151 277 1400 307"><b><u>Corporate History</u></b></p> <p data-bbox="606 343 1417 373">See provided graphic laying out Allergan's transactional history.</p> <p data-bbox="1138 414 1417 444"><b><u>Corporate Structure</u></b></p> <p data-bbox="606 480 1783 910">The corporate structure of all the entities identified below is shown in the following corporate organizational charts: 2011-01-05 ALLERGAN_MDL_03367307; 2011-01-21 ALLERGAN_MDL_03367302; 2012-10-12 ALLERGAN_MDL_03367301; 2012-11-30 ALLERGAN_MDL_02761472; 2012-12-31 ALLERGAN_MDL_03367304; 2013-01-24 ALLERGAN_MDL_02758853; 2013-06-30 ALLERGAN_MDL_02931208; 2013-10-01 ALLERGAN_MDL_01098786; 2014-01-31 ALLERGAN_MDL_01384578; 2014-06-30 ALLERGAN_MDL_03295845; 2014-12-31 ALLERGAN_MDL_02177059; 2015-01-01 ALLERGAN_MDL_02079795; 2015-09-08 ALLERGAN_MDL_01471538; 2015-09-30 ALLERGAN_MDL_02147315; 2016-01-01 ALLERGAN_MDL_01373731; 2016-03-31 ALLERGAN_MDL_02147111; 2016-08-03 ALLERGAN_MDL_03295865; 2016-09-30 ALLERGAN_MDL_03295869; 2017-06-30 ALLERGAN_MDL_00000006; 2017-08-01 ALLERGAN_MDL_00000001; 2018-03-31 ALLERGAN_MDL_03295860.</p> <p data-bbox="606 946 1306 976">Key Chart - 08-02-2016 ALLERGAN_MDL_03674501</p> <p data-bbox="1104 1012 1449 1042"><b><u>Involvement with Opioids</u></b></p> <p data-bbox="606 1078 1087 1108"><b>Transferred Entities/IP Ownership:</b></p> <p data-bbox="606 1144 1923 1286">Allergan sold its generic businesses to Teva in 2016. Teva - Allergan MPA (ALLERGAN_MDL_01481207). As part of that transaction, Allergan sold a number of entities to Teva that were involved with generic opioids. The following entities sold to Teva were listed as the ANDA or NDA holders for the following schedule II opioid products (see FDA "Orange Book"):</p> <ol data-bbox="708 1323 1119 1352" style="list-style-type: none"> <li>1. Watson Laboratories, Inc.</li> </ol>



NO	Topic	Response
		<p>(a) Fentanyl citrate injection (ANDA # 074917)</p> <p>(b) Fentanyl citrate table (ANDA # 079075)</p> <p>(c) Fentanyl transdermal (ANDA # 076709)</p> <p>(d) Hydrocodone / acetaminophen (ANDA #s 081083; 081080; 081079; 040094; 040122; 040123; 040099; 040148; 089883; 040248)</p> <p>(e) Meperidine Hydrochloride Injection (ANDA #s 073443; 073444; 073445)</p> <p>(f) Meperidine Hydrochloride Tablet (ANDA #s 040186)</p> <p>(g) Morphine sulfate injection (ANDA #s 073373; 073374; 073375; 073376)</p> <p>(h) Morphine sulfate capsule (ANDA #s 200812)</p> <p>(i) Oxycodone / acetaminophen (ANDA #s 040234; 040171; 040371; 040535)</p> <p>(j) Oxycodone / aspirin (ANDA #s 040255; 090084)</p> <p>(k) Oxycodone / ibuprofen (ANDA # 078394)</p> <p>(l) Morphine sulfate tablet (ANDA # 075656)</p> <p>2. Actavis Laboratories FL, Inc. f/k/a Watson Laboratories, Inc. - Florida</p> <p>(a) Hydrocodone / acetaminophen (ANDA #s 040493; 040494; 040495; 040148<sup>1</sup>; 206470)</p> <p>(b) Hydrocodone / ibuprofen (ANDA #s 077454; 076604)</p>

<sup>1</sup> Some products are listed under more than one entity if the ANDA or NDA transferred between the entities.

NO	Topic	Response
		<p>(c) Oxycodone / aspirin (ANDA # 090084)</p> <p>(d) Hydromorphone tablet (ANDA # 202144)</p> <p>3. Actavis Totowa LLC</p> <p>(a) Oxycodone / acetaminophen (ANDA #s 040203; 040199; 040800)</p> <p>(b) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 040295)</p> <p>(c) Oxycodone / hydrochloride tablet (ANDA # 076636)</p> <p>4. Actavis Elizabeth LLC</p> <p>(a) Oxycodone / acetaminophen (ANDA #s 040203; 040199; 040800; 201447)</p> <p>(b) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 040295)</p> <p>(c) Morphine sulfate capsule (ANDA #s 020616; 079040)</p> <p>(d) Morphine sulfate tablet (ANDA # 203849)</p> <p>(e) Oxycodone / hydrochloride tablet (ANDA # 076636)</p> <p>(f) Oxycodone / ibuprofen (ANDA # 078769)</p> <p>(g) Oxymorphone tablet (ANDA # 079046)</p> <p>5. Actavis Mid Atlantic LLC</p> <p>(a) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 088017)</p> <p>6. Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc. Salt Lake City</p>

NO	Topic	Response
		<p>(a) Morphine sulfate capsule (NDA # 020616)</p> <p>7. Actavis South Atlantic LLC</p> <p>(a) Oxymorphone tablet (ANDA # 079046)</p> <p>(b) Fentanyl transdermal (ANDA # 077602)</p> <p><b>Remaining Allergan Entities:</b></p> <p><u>Kadian®</u>: From December 19, 2005, until it purchased the medication, Actavis Elizabeth LLC served as the contract manufacturer of Kadian® for Alpharma. February 2, 2008 Actavis Elizabeth and Alpharma Contract (ALLERGAN_MDL_01076982); December 19, 2005, Alpharma - Purepac Contract (ALLERGAN_MDL_01474803).</p> <p>Actavis Elizabeth LLC acquired Kadian® from Alpharma in December 2008. December 17, 2008 Asset Purchase Agreement by and between King Pharmaceuticals, Inc. and Actavis Elizabeth, L.L.C. (ALLERGAN_MDL_01514893).</p> <p>The holders of the Kadian® NDA (020616) since December 2008 were and are (see FDA “Orange Book”):</p> <ul style="list-style-type: none"> <li>December 2008-2013: Actavis Elizabeth LLC</li> <li>2013-2016: Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc. - Salt Lake City</li> <li>2016-Present: Allergan Sales, LLC</li> </ul> <p>April 11, 2013 Transfer Letter (ALLERGAN_MDL_00811313); November 20, 2014, Company Name Change Letter (ALLERGAN_MDL_02195036); March 11, 2016 Transfer Letter (ALLERGAN_MDL_02197647).</p>

NO	Topic	Response
		<p>As part of the sale of its generic business to Teva, Teva agreed to continue manufacturing Kadian® and Norco for Allergan. Exhibit B of Teva-Allergan 2015 MPA (ALLERGAN_MDL_03367042). At that time, Allergan also contracted with UPS SCS, Inc. to distribute controlled substances, including Kadian® and Norco. 2015 UPS Allergan Contract ALLERGAN_MDL_01396729.</p> <p>Since December 2008, Kadian’s label has identified the following entities as the manufacturer or distributor of Kadian®: Actavis Elizabeth LLC; Actavis Kadian LLC; Actavis Pharma, Inc.; and Allergan USA, Inc. 02/2009 Label (ALLERGAN_MDL_02200691); 02/2010 Label (ALLERGAN_MDL_01132982); 07/2012 Label<sup>2</sup>; 04/2014 Label<sup>3</sup>.</p> <p>The current label (revised 09/2018<sup>4</sup>) states that Kadian® is distributed by Allergan USA, Inc.; however, Allergan USA, Inc. does not distribute Kadian® itself. Instead, after Allergan sold the entities with the DEA-registrations required to produce and distribute schedule II controlled substances, Allergan USA, Inc. has contracted with UPS SCS, Inc. to distribute Kadian® on its behalf. 2015 UPS Allergan Contract (ALLERGAN_MDL_01396729).</p> <p><u>Norco</u>: The holders of the Norco ANDAs (40099 &amp; 40148) were and are (<i>see</i> FDA “Orange Book”):</p> <p>ANDA 40099:</p> <ul style="list-style-type: none"> <li>• 1997-1999: UCB Pharmaceuticals, Inc.</li> <li>• 2000-2015: Watson Laboratories, Inc.</li> <li>• 2016: Allergan Sales, LLC</li> <li>• 2017-Present: Allergan Pharmaceuticals International Limited</li> </ul>

<sup>2</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/020616s041lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020616s041lbl.pdf)

<sup>3</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/020616s051lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020616s051lbl.pdf)

<sup>4</sup> [https://www.allergan.com/assets/pdf/kadian\\_pi](https://www.allergan.com/assets/pdf/kadian_pi)

NO	Topic	Response
		<p>ANDA 40148:</p> <ul style="list-style-type: none"> <li>• 1997-2014: Watson Laboratories, Inc.</li> <li>• 2015: Actavis Laboratories FL, Inc.</li> <li>• 2016: Allergan Sales, LLC</li> <li>• 2017-Present: Allergan Pharmaceuticals International Limited</li> </ul> <p>The following entities were involved in manufacturing and distributing Norco: Watson Pharma, Inc., Watson Laboratories, Inc., Warner Chilcott Company, LLC, Allergan USA, Inc., and Allergan Sales, LLC. 04/2002 Label (ALLERGAN_MDL_01095947); April 2003 Label (ALLERGAN_MDL_01095940); 07/2007 Label (ALLERGAN_MDL_01680965); 10/2009 Label (ALLERGAN_MDL_02206790); 06/2011 Labels (ALLERGAN_MDL_02209823; ALLERGAN_MDL_02210219); 08/2012 Label (ALLERGAN_MDL_01768757); 08/2013 Labels (ALLERGAN_MDL_02210402; ALLERGAN_MDL_02209867); 2014 Labels<sup>5</sup>; 02/2017 Label (ALLERGAN_MDL_02219168); Current Label<sup>6</sup>.</p> <p>Similar to Kadian®, after Allergan sold the entities with the DEA-registrations required to produce and distribute schedule II controlled substances, Allergan contracted with Teva and UPS, SCS Inc. to manufacture and distribute Norco on behalf of Allergan USA, Inc. and Allergan Sales, LLC. 2015 UPS Allergan Contract (ALLERGAN_MDL_01396729); Exhibit B of Teva-Allergan 2015 MPA (ALLERGAN_MDL_03367042).</p> <p><u>Other Schedule II Branded Drugs:</u> Between 2004 and 2006, Watson Pharmaceuticals, Inc., collaborated with Interpharm, Inc. (the ANDA holder) in the marketing and sale of Reprexain (ANDA 076642 - Hydrocodone bitartrate / ibuprofen). June 07, 2004 Email &amp; Press Release Announcing Launch</p>

<sup>5</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/040099Orig1s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040099Orig1s018lbl.pdf);  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/040148s053lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040148s053lbl.pdf)

<sup>6</sup> [https://www.allergan.com/assets/pdf/norco\\_pi](https://www.allergan.com/assets/pdf/norco_pi)

NO	Topic	Response
		<p>(ALLERGAN_MDL_01830938; ALLERGAN_MDL_01830941); June 14, 2006 Email Discussing No Longer Promoting Reprexain (ALLERGAN_MDL_01728789).</p> <p>On October 12, 2000, Watson Pharma, Inc. announced the addition of Maxidone (40094 - hydrocodone bitartrate / acetaminophen) to its product portfolio. October 12, 2000 Product Introduction Notification (ALLERGAN_MDL_02579713). Since 2015, Maxidone has been included on the FDA's list of discontinued drugs. (<i>See</i> 2015 FDA Orange Book, "Discontinued Drug Product List").</p> <p>Actavis acquired Forest Laboratories, Inc. in 2014. Prior to the acquisition, Forest Laboratories, Inc. sold a product called Combunox (021378 - Oxycodone Hydrochloride / ibuprofen). Forest received approval for Combunox on November 26, 2004. Since 2012, Combunox has been included on the FDA's list of discontinued drugs. (<i>See</i> 2012 FDA Orange Book, "Discontinued Drug Product List").</p>
43.2	<p>The management of the generic opioid business from 1995 to the present for all Allergan entities (including Allergan Finance, LLC, Allergan plc, and all subsidiaries, parents, predecessors, successors and/or associated entities resulting from any and all mergers over the years) and all generic opioids for which any Allergan entities had any involvement</p>	<p>Each of the seven entities identified above that had involvement with generic opioid medications is included on Schedule 4.6(g) of the Teva-Allergan MPA, which lists the entities transferred to Teva. Teva-Allergan MPA Schedules (ALLERGAN_MDL_03367048).</p> <p>The January 1, 2015, organization chart shows where each of these entities fell within the the corporate structure of Allergan prior to the sale to Teva. ALLERGAN_MDL_02079795. Actavis South Atlantic LLC, Actavis Elizabeth, LLC, Actavis Mid Atlantic LLC, and Actavis Totowa LLC were all direct subsidiaries of Actavis LLC, which was an indirect subsidiary of Watson Laboratories, Inc. <i>See id</i> at 2. Watson Laboratories, Inc. was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>See id</i>. Actavis Laboratories UT, Inc. was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>Id</i>. Actavis Laboratories FL, Inc. (f/k/a Watson Laboratories, Inc. - Florida) was a direct subsidiary of Andrx Corporation, which was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>Id</i>. Andrx Corporation and Actavis LLC, in addition to the seven generic ANDA-holding entities, were transferred to Teva. Teva-Allergan MPA Schedules (ALLERGAN_MDL_03367048).</p> <p>Prior to the sale of these entities to Teva, Actavis, Inc. n/k/a Allergan Finance, LLC did not manufacture, market, distribute, or sell any pharmaceutical products. It operated solely as a holding company. All of the direct subsidiaries of Actavis, Inc. n/k/a Allergan Finance involved in the management of the generic</p>

NO	Topic	Response
		<p>opioid business were transferred to Teva. No other affiliate of Allergan Finance LLC or Allergan plc had involvement with generic opioids.</p> <p><u>Officers &amp; Directors of Generic Entities:</u></p> <p>Based on a review of reasonably available documents, we have identified the following persons as directors and officers of some of the entities identified above.</p> <p><b><u>Watson Pharma, Inc.</u></b></p> <p><u>7-24-2012:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Ranjana B. Pathak, Andrew Boyer, Charles M. Mayr, Lynne Amato, Thomas R. Griffin, Tim Callahan, Diane Miranda, Kathleen Reape, Allan Slavsky, Michael W. Carr, Sigurd C. Kirk, James O'Brien, James A. Williamson, Brett W. Hagardorn.</p> <p><i>See ALLERGAN_MDL_03367292</i></p> <p><u>8-30-2013:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Ranjana B. Pathak, Andrew Boyer, Charles M. Mayr, Lynne Amato, Thomas R. Griffin, Tim Callahan, Kathleen Reape, Allan Slavsky, Michael W. Carr, Sigurd C. Kirk, James O'Brien, James A. Williamson, Brett W. Hagardorn, John Larocca.</p> <p><i>See ALLERGAN_MDL_03367295.</i></p> <p><b><u>Watson Laboratories, Inc.</u></b></p>



NO	Topic	Response
		<p><u>7-24-2012:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Patrick G. Brunner, Charles D. Ebert, Ranjana B. Pathak, Nick Kerkhof, Gary Kozloski, Gary Holloway, Jeffery Regan, Beth Brennan, Kathleen Reape, Michael W. Carr, James O'Brien, James A. Williamson, Miguel A. Gomez, Brett W. Hagadorn, Roberta Loomar.</p> <p><i>See ALLERGAN_MDL_03367294.</i></p> <p><u>8-30-2013</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Patrick G. Brunner, Charles D. Ebert, Ranjana B. Pathak, Hafrun Fridriksdottir, Nick Kerkhof, Gary Kozloski, Gary Holloway, Jeffery Regan, Beth Brennan, Kathleen Reape, Michael W. Carr, James O'Brien, James A. Williamson, Miguel A. Gomez, Brett W. Hagadorn, John Larocca.</p> <p><i>See ALLERGAN_MDL_03367296.</i></p>
43.3	All involvement and communications Allergan plc has had with any of its subsidiaries involved in the licensing, manufacture, marketing, sale, or distribution of any opioid products, including Allergan plc's ownership interests in, control over, and financial interrelationships with any	<p>Allergan plc "was established for the purpose of facilitating the business combination between Allergan Finance, LLC (formerly known as Actavis, Inc.) and Warner Chilcott plc." Allergan plc 2017 10-K at 3. Allergan Finance, LLC acquired Warner Chilcott plc in a stock-for-stock transaction in 2013. 5/19/2013 Actavis, Inc. 8-K at 9. After the transaction, Warner Chilcott and Allergan Finance, LLC each became wholly owned, indirect subsidiaries of Allergan plc. Allergan plc 2017 10-K at 3.</p> <p>Allergan plc f/k/a Actavis plc is an Irish corporation and its only offices are located in Ireland. Allergan plc is a holding company that exists for the purpose of holding shares of other companies that manufacture and distribute prescription drugs rather than producing or selling its own goods or services. Allergan plc does not finance or control the daily affairs, including marketing or sales operations, of its subsidiaries.</p>



NO	Topic	Response
	such subsidiaries, as well as how subsidiaries' management interacted with and reported to Allergan plc and how this changed over time.	<p>The following individuals are or were the primary executives at Allergan Finance, LLC in the following categories at the specified time period:</p> <p><b><u>Watson Pharmaceuticals, Inc.</u></b></p> <p><u>Officers</u></p> <ul style="list-style-type: none"> <li>(i) Chief Executive Officer: Allen Chao (1999-2008), Paul Bisaro (2008-2012)</li> <li>(ii) Chief Financial Officer: Michael Boxer (1999-2002), Charles Slacik (2003-2007), Mark Durand (2008-2009), R. Todd Joyce (2010-2012)</li> <li>(iii) Chief Operating Officer: Fred Wilkinson (1999-2000), Joseph Papa (2001-2004), Robert Stewart (2010-2012)</li> <li>(iv) General Counsel: Robert Funsten (1999-2001), David Buchen (2002-2012)</li> <li>(v) Sales: Lynne Amato (1999, 2003-2009), Carolyn Logan (1999), Andy Boyer (2003-2012), Tim Callahan (2010-2012)</li> <li>(vi) Marketing: Lynne Amato (1999, 2003-2012), Carolyn Logan (1999), Andy Boyer (2003-2012)</li> <li>(vii) Compliance: Roberta Loomar (2008-2010), Deborah Penza (2011-2012)</li> <li>(viii) Sales or Marketing Training: None</li> <li>(ix) Government Affairs: G. Thomas Long (2004-2010), Charlie Mayr (2011-2012)</li> <li>(x) Medical Director: Gary Kozloski (2001-2012)</li> <li>(xi) Research and Development: Charles Ebert (1999-2012), Francois Menard (2007-2012)</li> </ul> <p><u>Directors</u></p> <ul style="list-style-type: none"> <li>(i) Paul Bisaro (2007 - 2012)</li> <li>(ii) Christopher Bodine (2009 - 2012)</li> <li>(iii) Allen Chao (1983 - 2009)</li> <li>(iv) Michael Fedida (1995 - 2012)</li> <li>(v) Michael Feldman (1985 - 2012)</li> <li>(vi) Albert Hummel (1986 - 2012)</li> <li>(vii) Alec Keith (1991 - 2000)</li> <li>(viii) Catherine Klema (2004 - 2012)</li> <li>(ix) Jack Michelson (2002 - 2012)</li> </ul>


NO	Topic	Response
		<p>(x) Melvin Sharoky (1995 - 1998)</p> <p>(xi) Anthony Tabatznik (2009 - 2012)</p> <p>(xii) Ronald Taylor (1994 - 2012)</p> <p>(xiii) Andrew Turner (1997 - 2012)</p> <p>(xiv) Fred Weiss (2000 - 2012)</p> <p><b><u>Actavis, Inc.</u></b></p> <p><u>Officers:</u></p> <p>(i) Chief Executive Officer: Paul Bisaro (2013-2014), Brent Saunders (2015-2016)</p> <p>(ii) Chief Financial Officer: Todd Joyce (2013-2014), Tessa Hilado (2015-2016)</p> <p>(iii) Chief Operating Officer: Robert Stewart (2013-2016)</p> <p>(iv) General Counsel: David Buchen (2013-2014), A. Robert D. Bailey (2015-2016)</p> <p>(v) Sales: Andy Boyer (2013), Tim Callahan (2013), Siggi Olafsson (2013-2014), William Meury (2015-2016)</p> <p>(vi) Marketing: Andy Boyer (2013), Lynne Amato (2013), Siggi Olafsson (2013-2014), William Meury (2015-2016)</p> <p>(vii) Compliance: Debra Penza (2013-2014), Joseph Zimmerman (2014), Jonathon Kellerman (2015-2016)</p> <p>(viii) Sales or Marketing Training: None</p> <p>(ix) Government Affairs: Charlie Mayr (2013-2014), Alex Kelly (2015-2016)</p> <p>(x) Medical Director: Gary Kozlowski (2013), Gavin Corcoran (2014-2016)</p> <p>(xi) Research and Development: Chuck Ebert (2013-2014), Hafrun Fridriksdottir (2013-2014), David Nicholson (2015-2016)</p> <p><u>Directors</u></p> <p>(i) Paul Bisaro (2013-2014)</p> <p>(ii) Christopher Bodine (2013-2014)</p> <p>(iii) Michael Fedida (2013-2014)</p> <p>(iv) Michael Feldman (2013-2014)</p> <p>(v) Albert Hummel (2013-2014)</p> <p>(vi) Catherine Klerna (2013-2014)</p>

NO	Topic	Response
		<p>(vii) Jack Michelson (2013-2014)</p> <p>(viii) Ronald Taylor (2013-2014)</p> <p>(ix) Andrew Turner (2013-2014)</p> <p>(x) Fred Weiss (2013-2014)</p> <p><b><u>Allergan Finance, LLC</u></b></p> <p><u>Officers</u></p> <p>Allergan Finance, LLC's management structure is set forth in the Second Amended and Restated Operating Agreement of Allergan Finance, LLC (ALLERGAN_MDL_SUPP_00000326). This Operating Agreement identifies the following officers:</p> <p>(i) A. Robert D. Bailey</p> <p>(ii) Matthew M. Walsh</p> <p>(iii) Jonathon Kellerman</p> <p>(iv) Karen Ling</p> <p>(v) Alex Kelly</p> <p>(vi) William Meury</p> <p>(vii) Sigurd Kirk</p> <p>(viii) Marc Princen</p> <p>(ix) James D'Arecca</p> <p>(x) Sean Lennon</p> <p>(xi) David Nicholson</p> <p>(xii) Lynne Bolduc</p> <p>(xiii) Thomas Poche</p> <p>(xiv) Brian Anderson</p> <p>(xv) Riccardo Mancuso</p> <p>(xvi) Martin Shindler</p> <p>(xvii) Wayne Swanton</p> <p>(xviii) Stephen M. Kaufhold</p> <p>(xix) Kira Schwartz</p> <p>(xx) Judith Tomkins</p>

NO	Topic	Response
		<p><u>Directors</u>  Allergan Finance, LLC does not have a Board of Directors. Allergan Finance, LLC instead has a two-person Board of Managers that is comprised of A. Robert D. Bailey and Matthew M. Walsh.</p> <p><b><u>Allergan plc Board &amp; Executive Leadership Team:</u></b></p> <p><b>10-02-2013<sup>7</sup></b></p> <p><u>Directors:</u></p> <ul style="list-style-type: none"> <li>(i) Paul M. Bisaro</li> <li>(ii) James H. Bloem</li> <li>(iii) Christopher Bodine</li> <li>(iv) Tamar D. Howson</li> <li>(v) John A. King</li> <li>(vi) Catherine M. Klema</li> <li>(vii) Jiri Michal</li> <li>(viii) Jack Michelson</li> <li>(ix) Sigurdur Oli Olafsson</li> <li>(x) Patrick J. O'Sullivan</li> <li>(xi) Andrew L. Turner</li> <li>(xii) Fred G. Weiss</li> </ul> <p><b>Current Leadership:</b></p> <p><u>Executive Leadership Team:</u></p> <ul style="list-style-type: none"> <li>(i) Brenton L. Saunders, Chairman, President and CEO</li> <li>(ii) William Meury, EVP &amp; Chief Commercial Officer</li> <li>(iii) Matt Walsh, EVP &amp; Chief Financial Officer</li> <li>(iv) A. Robert D. Bailey, EVP &amp; Chief Legal Officer and Corporate Secretary</li> <li>(v) Karen L. Ling, Esq., EVP &amp; Chief Human Resources Officer</li> </ul>

<sup>7</sup> <https://www.allergan.com/news/news/thomson-reuters/actavis-plc-names-board-of-directors>

NO	Topic	Response
		<p>(vi) C. David Nicholson, PhD, EVP &amp; Chief R&amp;D Officer</p> <p>(vii) Alex Kelly, EVP &amp; Chief Communications Officer</p> <p>(viii) Wayne R. Swanton, EVP, Global Operations</p> <p><u>Directors</u></p> <p>(i) Nesli Basgoz, M.D.</p> <p>(ii) Joseph H. Boccuzzi</p> <p>(iii) Christopher W. Bodine</p> <p>(iv) Adriane M. Brown</p> <p>(v) Christopher J. Coughlin</p> <p>(vi) Carol Anthony (John) Davidson</p> <p>(vii) Michael E. Greenberg, PhD</p> <p>(viii) Thomas C. Freyman</p> <p>(ix) Catherine M. Klema</p> <p>(x) Peter J. McDonnell, M.D.</p> <p>(xi) Fred G. Weiss</p>



EXECUTION VERSION  
CONFIDENTIAL

**Schedule 1.1 – Brand R&D Assets**

EXECUTION VERSION  
CONFIDENTIAL

Brands R&D Projects		Elizabeth, NJ	Larne, Northern Ireland	Salt Lake City	Other Other Sites (Drug Product)	API
Armour Thyroid	T3 , T4					
Bystolic	Nebivolol					
Byvalson (NAC)	Nebivolol, Valsartan					
TRV-027	TRV-027				Nerviano	Ambernath
Vraylar	Cariprazine					
Fetzima	Levomilnacipran					
Namenda XR	Memantine					
Namzaric (MDX)	Memantine, Donepezil					
Saphris	Asenapine					
Viibryd	Vilazodone					
AGN237396						
AGN241607	B63-a					Ambernath
Gelnique	Oxybutynin					
Oxybut. for hyperhydrosis	Oxybutynin					
Sarecycline	WC3035					Ambernath
Asacol 800 WC3046						
Asacol 400 WC3079	Mesalamine					
Carafate, Sulcrate	Sucralphate					
Viberzi	Eluxadoline					Ambernath
Linzess	Linaclotide					
Zenpep	Pancreatic enzyme					
Pylera	Bi/tetracycl./metro.					
Rectiv	Nitroglycerine					
RM-131	Relamorelin					



Teflaro	Ceftaroline fosamil				
AVYCAZ	Ceftazidime,avibactam				
CXL	Ceftaroline, avibactam				
Dalbance	Dalbavancin				
ATM-AVI	Aztreonam-avibactam				
Colobreathe	Colistimethate Na				
Enablex WC3059	Darifenacin		TBC	TBC	
Rapaflo	Silodosin				Dupnitsa
Diafert	Immunoassay kit				
Esmya	Ulipristal acetate		TBC		
Est..capsule WC3037	Estradiol				Fajardo
Est. cream WC3011	Estradiol				Fajardo
Etonog. Ring WC3058	Etonogestrel				
Levosert/ Liletta	Levonorgestrel IUD				
Loyelle/Loestrin WC3081	Norethindrone Ac ,EE				Fajardo
Minestrin	Norethindrone Ac ,EE				Fajardo
Nuessa	Metronidazole gel				
InFed	Ion dextran				
PEG beads	(Phoenix project)				

**Schedule 1.1(a) – Excluded Products**

- Manufactured Products, as agreed on the date of the Agreement and as defined in the Term Sheet for the Manufacturing Agreement set out as Exhibit B to the Agreement.
- Androderm
- Aquadeks
- Asacol
- Diafert
- Eziclen
- Levoser
- Oxytrol
- Panzytrat
- Pylera
- Rapaflo
- Bendamustine HCl (Treanda ANDA #204208)
- Viibryd

**Schedule 1.1(b) – International Generics Products**

The products shown on the workbook entitled “International Gx Product List” in the Excel file entitled “SC1-#3914718-v1-Product\_Schedule.xlsx”, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark of Latham & Watkins at 03.04 AM on July 27, 2015.

**Schedule 1.1(c) – OTC Products**

The products shown on the workbook entitled “US Product Gx List” in the excel file entitled “SC1-#3914718-v1-Product\_Schedule.xlsx”, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark of Latham & Watkins at 03.04 AM on July 27, 2015.

**Schedule 1.1(d) – Seller Parent’s Knowledge**

- Paul M. Bisaro, Executive Chairman
- Brenton L. Saunders, Chief Executive Officer and President
- Robert Stewart, President, Generics and Global Operations
- Maria Teresa Hilado, Chief Financial Officer
- A. Robert D. Bailey, Chief Legal Officer and Corporate Secretary
- Karen Ling, Chief Human Resources Officer
- Jonathon Kellerman, Global Chief Compliance Officer

**Schedule 1.1(e) – Transferred Brand Products**

The products shown on the workbook entitled “Transferred Brands” in the excel file entitled “SC1-#3914718-v1-Product\_Schedule.xlsx”, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark of Latham & Watkins at 03.04 AM on July 27, 2015.

**Schedule 1.1(f) – Transferred Entities**

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
1. Warner Chilcott Company, LLC	Puerto Rico
2. Warner Chilcott (Ireland) Limited	Ireland
3. Warner Chilcott Australia Pty. Ltd.	Australia
4. Warner Chilcott Pharmaceuticals B.V.B.A.	Belgium
5. Warner Chilcott France SAS	France
6. Warner Chilcott Italy S.r.l.	Italy
7. Actavis Pharma Iberia S.L. (f/k/a Warner Chilcott Iberia S.L.)	Spain
8. Robin Hood Holdings Ltd.	Malta
9. Paomar plc	Cyprus
10. Actavis Pharma Pty Ltd.	Australia
11. Actavis Holding 2 Sàrl	Luxembourg
12. Actavis S.à.r.l.	Luxembourg
13. Actavis Pharma Holding 4 ehf. (APH4)	Iceland
14. Forest Laboratories UK Ltd.	UK
15. Forest Pharma BV	Netherlands
16. Axcan France (Invest) SAS	France
17. Makoff R&D Laboratories, Inc.	California
18. Royce Laboratories, Inc.	Florida
19. The Rugby Group, Inc.	New York
20. Watson Pharmaceuticals (Asia) Ltd.	BVI
21. Nicobrand Limited	Northern Ireland

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
22. Watson Pharmaceuticals International Ltd.	BVI
23. Watson Diagnostics, Inc.	Delaware
24. Del Mar Indemnity Co. Inc.	Hawaii
25. Actavis Laboratories NY, Inc.	New York
26. Andrx Corporation	Delaware
27. Watson Cobalt Holdings, LLC	Delaware
28. Watson Manufacturing Services, Inc.	Delaware
29. Allergan UK LLP	UK
30. Forest Tosara Ltd.	Ireland
31. Actavis Laboratories UT, Inc.	Delaware
32. Watson Laboratories, Inc.	Nevada
33. Actavis Pharma, Inc.	Delaware



**Schedule 1.1(g) – U.S. Generics Products**

The products shown on the workbook entitled “US Product Gx List” in the excel file entitled “SC1-#3914718-v1-Product\_Schedule.xlsx” to the extent such products are not over the counter (non-prescription) products, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark of Latham & Watkins at 03.04 AM on July 27, 2015.

**Schedule 1.1(h) – Authorized Generic List of Own Brand Products**

#	Generic Name	Dosage Form	Brand Equivalent
1	Butalbital/Acetaminophen/Caffeine	Immediate Release Tablets	Fioricet®
2	Butalbital/Acetaminophen/Caffeine/Codeine Phosphate	Immediate Release Capsules	Fioricet® with Codeine
3	Butalbital/Aspirin/Caffeine	Immediate Release Capsules	Fiorinal®
4	Codeine Phosphate/Butalbital/Aspirin/Caffeine	Immediate Release Capsules	Fiorinal® with Codeine
5	Escitalopram Oxalate	Oral Solution	Lexapro®
6	Estradiol	Immediate Release Tablets	Estrace ®
7	Ethinyl Estradiol/Norethindrone (Layolis Fe)	Immediate Release Tablets	Generess Fe®
8	hydrochlorothiazide	Immediate Release Capsules	Microzide®
9	Hydrocodone Bit/Acetaminophen	Immediate Release Tablets	Norco®
10	Hydrocodone Bit/Acetaminophen	Immediate Release Tablets	Norco® 5MG/325MG
11	Hydrocodone Bit/Acetaminophen	Immediate Release Tablets	Norco® 7.5MG/325MG
12	Lidocaine/Prilocaine	Topical Cream	Emla®
13	Loxapine Succinate	Immediate Release Capsules	Loxitane®
14	Morphine Sulfate ER	Modified Release Capsules	Kadian®
15	Namenda	Immediate Release	Namenda®

		Tablets	
16	Norethindrone (Nora-Be)	Immediate Release Tablets	Nor-QD®
17	Norethindrone A-E Estradiol/Ferrous Fumarate (Tilia)	Immediate Release Tablets	Estrostep®Fe
18	Norethindrone-Ethinyl Estradiol (Leena)	Immediate Release Tablets	Tri-Norinyl®
19	Norethindrone-Ethinyl Estradiol (Necon)	Immediate Release Tablets	Norinyl® 1/50 (Norethindrone/Mestranol)
20	Norethindrone-Ethinyl Estradiol (Zenchent)	Immediate Release Tablets	Ovcon®
21	Norethindrone-Ethinyl Estradiol/Ferrous Fumarate (Zenchent Fe)	Immediate Release Tablets	Femcon FE®
22	Oxazepam	Immediate Release Capsules	Serax®
23	Podofilox	Topical Solution	Condylox® Solution
24	Risedronate DR	Modified Release Tablets	Atelvia®
25	Risedronate Sodium	Modified Release Tablets	Actonel®
26	Risedronate Sodium	Immediate Release Tablets	Actonel®
27	Ursodiol	Immediate Release Capsules	Actigall®
28	Ursodiol	Immediate Release Tablets	Urso 250®
29	Ursodiol	Immediate Release Tablets	Urso Forte®
30	Sucralfate	Immediate Release Tablets	Carafate®

**Schedule 1.1(i) – Puerto Rico Grant**

COMMONWEALTH OF PUERTO RICO  
DEPARTMENT OF ECONOMIC DEVELOPMENT AND COMMERCE  
OFFICE OF INDUSTRIAL TAX EXEMPTION

Grant of Tax Exemption to WARNER CHILCOTT COMPANY, LLC and PROCTER & GAMBLE PHARMACEUTICALS PUERTO RICO LLC (hereinafter referred to as, "applicants" or "Grantees"), Case No. 09-73-I-47, pursuant to the terms of Act No. 73 of May 28, 2008 (hereinafter referred to as the "Act");

DECREE

WHEREAS, the Act empowers the Secretary of the Department of Economic Development and Commerce of the Commonwealth of Puerto Rico to Grant tax exemption from specified taxes to eligible industries when it is proved to the satisfaction of the Secretary of the Department of Economic Development and Commerce that the applicants has established, or will establish, an eligible industry as defined in the Act and that the same will be in the best interest of Puerto Rico;

WHEREAS, the Secretary of the Department of Economic Development and Commerce of the Commonwealth of Puerto Rico, after having examined the report of the Special Examiner, the report of the Executive Director of the Puerto Rico Industrial Development Company, and other documents relative to this case, is of the opinion that the applicants has proved that it will operate an eligible industry within the meaning of the Act and that the same will be in the best interest of Puerto Rico;

NOW, THEREFORE, BE IT DECREED BY THE SECRETARY OF THE DEPARTMENT OF ECONOMIC DEVELOPMENT AND COMMERCE OF THE COMMONWEALTH OF PUERTO RICO, that the applicants WARNER CHILCOTT COMPANY, LLC ("WCCL") and PROCTER & GAMBLE PHARMACEUTICALS PUERTO RICO LLC ("P&G Pharma"), be hereby granted tax exemption in accordance with the applicable terms of the Act, covering the following activities: (1) the manufacturing of the following products: chemical products: nitrofurantoin in its micro and macro crystalline form, dantrolene sodium, etidronate sodium (EHDP), and chemical intermediates thereof, which are useful in the manufacturing of nitrofurantoin, dantrolene and dantrolene sodium, and etidronate sodium as bulk or fine chemicals, and pharmaceutical products: nitrofurantoin in its micro and macro crystalline form, in the form of liquid suspensions, tablets and capsules; and Didronel (etidronate sodium) granulation and tablets, actonel, stedicor, Dantrium capsules, such as dantrolene sodium, in a sustained release or "long acting" or "repeat action" tablet and/or capsule form, and any related derivative or next generation products of such pharmaceutical products; (2) the manufacturing and packaging of any other pharmaceutical products, including but not limited to tablets, semi solids and capsules for pharmaceutical products; (3) contract manufacturing of pharmaceutical products; (4) contract manufacturing or toll processing of pharmaceutical products for other related or unrelated companies including, without limitation, the conversion of raw materials into goods in process or finished goods; warehousing of raw materials, goods in process or finished products; logistics or administration services in connection with raw materials, packaging materials, goods in process or finished goods, product supply, and any other activity related to the manufacturing of the products and or necessary to conduct the manufacturing operations by the applicants and/or other parties; provided that the raw materials, goods in process or finished goods may be either owned by any of the Grantees or the other contracting party; (5) the distribution of products manufactured by other entities on behalf of the applicants under contract manufacturing agreements; (6) import of products for their distribution to foreign markets; (7) the distribution of products that will not enter into Puerto Rico (drop shipments); (8) the licensing of intangible assets to companies in Puerto Rico or outside of Puerto Rico; and (9) import of the products Doryx, Pyridium, and Pyridium Plus, as well as any other products for distribution to foreign markets, provided that the operations shall be carried out as described in the application;

BE IT FURTHER DECREED, that pursuant to Section 13(a) (2) (G) of the Act and Administrative Order No. 0002-2008 of September 2, 2008, the Secretary of the Department of Economic Development and Commerce of the Commonwealth of Puerto Rico authorized the Director of the Office of Industrial Tax Exemption to carry on administrative duties of all nature, related with Grants of tax exemption issued under the provisions of the Act, including the approval or denial of tax exemption Grants for property devoted to industrial development, but excluding the authority to approve or deny tax exemption Grants to manufacturing or service units and any other duty specifically bestowed upon him by the Act;

BE IT FURTHER DECREED, that the Grantees herein shall be entitled to an exemption period of fifteen (15) years. The locations of the exempted businesses are at the municipalities of Fajardo and Manatí, Puerto Rico. The effective date of said tax exemption for WCCL shall be September 17, 2009 for income tax purposes and for municipal license and other municipal taxes purposes; and January 1, 2010, for real and personal property tax purposes. The effective date for P&G Pharma shall be October 30, 2009, for income tax purposes; and January 1, 2010, for real and personal property tax purposes and for municipal license and other municipal taxes purposes;

BE IT FURTHER DECREED, that with the approval of this Grant, WCCL shall surrender the remainder exemption period for Case No. 04-135-I-29, effective from September 16, 2009, for income tax purposes and for municipal license and other municipal taxes purposes; and December 31, 2009, for real and personal property tax purposes; PROVIDED FURTHER, that P&G Pharma shall surrender the remainder of their exempt period for the operations at Manatí on the Grant 00-135-I-18, effective October 30, 2009, for income tax purposes; and December 31, 2009, for real and personal property tax purposes and for municipal license and other municipal taxes purposes;

BE IT FURTHER DECREED, that as an essential condition to this Grant, P&G Pharma shall request that the grant of tax exemption under Case No. 00-135-I-18, be amended to reflect that Procter & Gamble Pharmaceuticals Puerto Rico LLC and its operations at Manatí, Puerto Rico, shall not be covered under such Grant, effective as of October 30, 2009;

BE IT FURTHER DECREED, that the Grantees are authorized to perform contract manufacturing activities pursuant to Section 2(f) of the Act;

BE IT FURTHER DECREED, that pursuant to Section 3(a) (2) of the Act, and during the term of this Grant, the Grantees shall be subject to a fixed income tax rate of two percent (2%) on its industrial development income ("IDI") derived from the manufacturing operations, the services activities, the licensing activities and the contract manufacturing activities covered by this Grant, in lieu of any other income tax rate; PROVIDED FURTHER, that the fixed income tax rate will not be subject to a Base Period Income pursuant to Section 3(g) of the Act, as recommended by the Puerto Rico Industrial Development Company at the Eligibility Report and Supplementary Reports for this case;

BE IT FURTHER DECREED, that on current distributions and on total liquidations, the industrial development income accumulated by WCCL starting on September 17, 2009, shall be totally exempt pursuant to Sections 3(d) (1) and (4) of the Act;

BE IT FURTHER DECREED, that on current distributions and on total liquidations, the industrial development income accumulated by P&G Pharma starting on October 30, 2009, shall be totally exempt pursuant to Sections 3(d) (1) and (4) of the Act;

BE IT FURTHER DECREED, that on current distributions and on total liquidations, the IDI accumulated by WCCL up to September 16, 2009, shall be totally exempt pursuant to Sections 7 and 10 of Act No. 135 of December 2, 1997 ("Act No. 135");

BE IT FURTHER DECREED, that on current distributions and on total liquidations, the IDI accumulated by P&G Pharma from July 1, 2001 through October 30, 2009 shall be totally exempt pursuant to Sections 7 and 10 of Act No. 135;



BE IT FURTHER DECREED, that distributions, as dividends, of IDI accumulated by P&G Pharma as of June 30, 2001, shall be subject to taxation according to the provisions of Act No. 26 of June 2, 1978, as amended ("Act No. 26");

BE IT FURTHER DECREED, that total liquidation of IDI accumulated by P&G Pharma from January 1, 1987 through June 30, 2001, shall be subject to taxation according to the provisions of Act No. 8 of January 24, 1987, as amended;

BE IT FURTHER DECREED, that total liquidation of IDI accumulated by P&G Pharma up to December 31, 1986, shall be taxed as provided in Act No. 26;

BE IT FURTHER DECREED, that pursuant to Section 3(c) of the Act, the IDI derived from investments on eligible activities under Section 2(j) of the Act, shall be totally exempt from income taxes and any other taxation;

BE IT FURTHER DECREED, that to the extent allowed and/or contemplated by the Act, the Grantees shall not be subject to any additional tax measured by reference to income or revenues, withholding taxes, property taxes, or municipal taxes; provided that any income tax overpayments attributable to the fixed income tax rates provided in this grant shall be creditable against Grantees' income tax liabilities arising in other taxable years:

BE IT FURTHER DECREED, that as provided by Section 7(a) of the Act, the Grantees, shall enjoy ninety percent (90%) exemption from municipal and Commonwealth personal and real property taxes, used in the development, organization, construction, establishment or operation of the activity covered under the grant, during the exemption period provided by Section 10 of the Act, starting on January 1, 2010;

BE IT FURTHER DECREED, that intangible personal property in the nature of patent, production license, or trademark acquired by the Grantees, as well as the shares of stock, bonds and other securities held by the Grantees, shall be totally exempt from the payment of property taxes:

BE IT FURTHER DECREED, that the effective date of this Grant for municipal license tax purposes will be September 17, 2009, for WCCL and January 1, 2010, for P&G Pharma. The Grantees will continue to be sixty percent (60%) exempt with respect to the municipal license tax payments and other municipal taxes imposed by any municipal ordinance, due on September 17, 2009, for WCCL, and January 1, 2010, for P&G Pharma, as provided by Section 8 (a) of the Act;

BE IT FURTHER DECREED, that pursuant to Section 3(b) (3) of the Act, the royalty payments that the Grantees make to non-residents of Puerto Rico will be subject to a withholding tax of ten percent (10%);

BE IT FURTHER DECREED, that pursuant to Section 2(a) (6) of the Act, the IDI subject to a fixed income tax rate of two percent (2%), will include any net income derived in connection with intangible property or any other right to receive income related to activities or intangible property owned or possessed by the Grantees, including, without limitation, income related to the sale of products manufactured under the intangible property (even if manufactured outside of Puerto Rico), royalties, up-front fees, and milestone payments, and any net gains from the sale of the intangible property;

BE IT FURTHER DECREED, that the minimum tax payment pursuant to Section 5(h) of the Act, shall be the fixed income tax rate of two percent (2%), considering as payment of such minimum tax any amounts withheld on royalty payments;

BE IT FURTHER DECREED, that in the case the Grantees is eligible for any of the credits provided by Sections 5 and 6 of the Act, the same shall be subject to the limitations imposed by Section 5(h) of the Act;

BE IT FURTHER DECREED, that this Grant shall be subject to the condition that the Grantees maintain the export billings of the services herein contemplated at a minimum annual volume of \$5,000,000 within twelve (12) months after the effectiveness of this Grant;

BE IT FURTHER DECREED, that as an essential condition to the issuance and continuance of this Decree, Grantees must comply with a combined employment commitment of three hundred and ninety (390) persons in its manufacturing operations and ten (10) persons in its service activities within the twelve (12) months after the effectiveness of this Grant, and must always continue to so directly employ at least said number of individuals; PROVIDED FURTHER, that to comply with the combined employment requirement of four hundred (400) persons, the Grantees can be allowed to consider full-time, part-time, temporary employees and employees for hire from employment agencies or other third parties rendering services to the Grantees in connection with its exempt operations; PROVIDED, that for purposes of compliance with the minimum employment requirement herein established, the Grantees shall not count people employed by the corporations that subcontract the Grantees, affiliated entities of the Grantees or other entities doing business in Puerto Rico, unless any employee counted by the Grantees are not counted by that other entity for purposes of determining compliance of its own minimum employment requirement, if any; PROVIDED, that commencing with the first full fiscal year of operations under the Grant after the effective date of the Grant, compliance with said employment requirement shall be determined on an average annual basis, using the weekly employment level and the fiscal year of the Grantees, and the average employment level shall likewise apply during any partial fiscal year of operations prior to the date of ceasing operations under the Grant;

BE IT FURTHER DECREED, that in determining the weekly employment level of direct employees, in order to calculate the Grantees' annual average employment level, the Grantees could include in such calculation any and all employees deemed inactive due to temporary leaves as a result of maternity, non-occupational disability, workmen's compensation related claims, and any other in similar work license;

BE IT FURTHER DECREED, that in determining the weekly employment level of temporary employees, part-time employees, and employees from employment agencies, in order to calculate the Grantees' annual average employment level, the Grantees shall compute the weekly full time equivalent employment level by dividing the total number of man-hours for a particular week by forty (40) hours;

BE IT FURTHER DECREED, that in determining the weekly employment level of employees, in order to calculate the Grantees' annual average employment level, plant shutdowns resulting from strikes, war, actions of the government, or the elements, plant shutdowns for regular maintenance of the facilities as per industry standard, or any other reasonable cause beyond the control of the Grantees shall not be taken into account;

BE IT FURTHER DECREED, that the employment requirement for the service activities mentioned above shall not include the company owners, nor employees of Grantees' associated local concern or employees of the Grantees that renders services for the local market;

BE IT FURTHER DECREED, that the Grantees must always comply with the employment requirement of the preceding clause, except in cases of unforeseen circumstances which may cause a reduction of employment beyond the control of Grantees, at which occurrence, or at the earliest date when such occurrence is contemplated, the Grantees shall be subject to one of the following alternatives:

1. If the reduction represents ten percent (10%) or less of the employment requirements, the Grantees has no obligation to notify the Office of Industrial Tax Exemption of said reduction;
2. If the reduction represents more than ten percent (10%) but less than twenty five percent (25%) of the employment requirement, Grantees shall notify within thirty (30) days after such reduction occurs, the Office of Industrial Tax Exemption, with copy to the Department of Labor and Human Resources of



Puerto Rico and the Industrial Development Company, of said reduction of employees on a sworn statement sent by certified mail with return receipt requested, or in the alternative, shall file said sworn statement personally at the Office of Industrial Tax Exemption with copy to the Department of Labor and Human Resources of Puerto Rico and the Industrial Development Company;

3. If the reduction represents twenty five percent (25%) or more of the employment requirement, the Grantees shall file within thirty (30) days after such reduction occurs, to the satisfaction and acceptance, which acceptance shall not be unreasonably withheld, with the Office of Industrial Tax Exemption a sworn application, with copy to the Department of Labor and Human Resources of Puerto Rico and the Industrial Development Company requesting approval of the Office of Industrial Tax Exemption for said reduction; PROVIDED, that the Office of Industrial Tax Exemption shall make a determination of such application as to whether Grantees shall be deemed to be in compliance with the employment requirement taking into consideration such reasonable grounds for reduction of employment, as for example, but not limited to, strikes, war, action of a government or of the elements, or any other reasonable cause beyond the control of the Grantees; PROVIDED, FURTHER, that it may, in lieu of the cancellation of the Decree on those cases in which the reduction of twenty five percent (25%) or more of the employment requirement is not approved:

- a. increase the fixed income tax rate and reduce the tax exemption percentages applicable to property and municipal licenses proportionately in a ratio which bears the relation between the reduced employment to the employment requirement; and/or
- b. approve a temporary reduction of the employment requirement when circumstances so merit by negotiating any other reasonable condition satisfactory both to the Grantees and the Commonwealth of Puerto Rico, and, a waiver of the employment requirement will be Granted when in the judgment of the pertinent Government agencies such terms of the negotiation further the purposes of industrial development under this Act;

*41*  
BE IT FURTHER DECREED, that Grantees are waived from compliance with the eighty percent (80%) employment level requirement established pursuant to Sections 3(a) (2) and 3(b) (3) of the Act.

BE IT FURTHER DECREED, that notwithstanding the preceding clause, the Grantees herein shall be subject to the following conditions, in regard of the herein exempt service activities:

1. Eighty percent (80%) of its employees, technicians and/or professionals shall be residents of Puerto Rico;
2. Such services shall not be utilized directly or indirectly in Puerto Rico, except those to be rendered to another firm in Puerto Rico that ultimately exports the designated service product;

BE IT FURTHER DECREED, that if at any time during the effectiveness of this Grant such services are utilized directly or indirectly in Puerto Rico, the provisions of this Grant shall not be applicable, and, therefore, such services shall be fully taxable, except those that fall within the exception mentioned in the paragraph above;

BE IT FURTHER DECREED, that the Grantees shall make all possible efforts to hire its production workers from the unemployed labor force listed in the Employment Service Division of the Bureau of Employment Security of the Department of Labor and Human Resources of Puerto Rico;

BE IT FURTHER DECREED, that if the income of the Grantees or any affiliate of the Grantees is adjusted by a firm and final order of the U.S. Internal Revenue Service pursuant to the United States Internal Revenue Code of 1986, as amended, or by the appropriate tax administration agency or competent authority of any foreign jurisdiction under any comparable and applicable statute of said foreign jurisdiction (hereafter the "Adjustment"), and the Adjustment involved or implied an actual, deemed or implicit decrease or increase, in attributions, assignments, allocations, or imputations made from the Grantees to or from any affiliates thereof in the taxable income of said Grantees as said taxable income had been previously determined by the Grantees on a Puerto Rico income tax return, or would otherwise reflect a tax position inconsistent with a tax reporting position taken by the Grantee for Puerto Rico income tax (including non-resident withholding tax) purposes and if by a reason of said inconsistent tax treatment or tax reporting position the Grantee or its affiliate may be subject to inconsistent tax treatment and/or potential double taxation, the Commonwealth of Puerto Rico, through the Puerto Rico Treasury Department may issue a credit to the Grantees, without interest, for any excess income taxes previously paid; provided, that if the effect of the Adjustment were an actual, deemed or implicit increase in the Puerto Rico taxable income of the Grantees, the Grantees shall show an amount equal to the Adjustment on an amended Puerto Rico income tax return or the Grantees shall enter into a Closing Agreement with the Puerto Rico Treasury Department and shall pay the corresponding taxes, without the imposition of any interest, surcharges, penalties, or other additions (hereafter the "Correlative Adjustment"). The Grantee acknowledges that the Puerto Rico Treasury Department, under the provisions of the Tax Coordination Agreement entered into between the Puerto Rico Treasury Department and the United States Internal Revenue Service, enacted Circular Letter 06-04 establishing the procedure to request assistance under the Mutual Agreement Procedure on potential double taxation established in the Tax Coordination Agreement between the United States and Puerto Rico. The Grantees shall follow the procedure established in the Circular Letter whenever a situation that would give rise to an Adjustment would require a Correlative Adjustment;

4/ BE IT FURTHER DECREED, that the gross Puerto Rico income and Puerto Rico taxable income of those Grantees that have in effect an election under Section 936 of the United States Internal Revenue Code of 1986, as amended, shall conform with the gross income and taxable income of the grantees for purposes of the United States Internal Revenue Code of 1986, as amended; provided, that any cost sharing, profit split, royalty, or other analogous, comparable, or equivalent payments, attributions, assignments, allocations, or imputations made from the Grantees to any affiliates thereof in order to reflect the gross income and taxable income of the grantees or other affiliates for purposes of the United States Internal Revenue Code of 1986, as amended, shall be removed and excluded from, and shall reduce, the Grantees' gross income, taxable income and volume of business for Puerto Rico tax purposes; and provided, that any such payments, attributions, assignments, allocations, or imputations that are made to other affiliates shall be one hundred percent (100%) exempt from income taxes, including income taxes withheld at source, and from municipal license taxes, as provided in Article 1042-7 of the Regulations issued under the Code;

BE IT FURTHER DECREED, that during the term of this Grant, the Grantees will be entitled to all of the benefits, exemptions and special tax rates available under the Act in effect on the date the Grant is signed, to the extent not inconsistent with any special provisions of this Grant; provided, that Grantees shall have the option of availing themselves of any benefits which may in the future become generally available under the Puerto Rico Internal Revenue Code of 1994, as amended, the Act and its regulations, or any successor statute, as these statutes may be amended from time to time;

BE IT FURTHER DECREED, that this Grant shall be subject to the continuing condition that the Grantees shall be required to keep its corporate books and accounts in Puerto Rico;

BE IT FURTHER DECREED, that during the period of effectiveness of this Grant the Grantees shall acquire no property and take no other action forbidden by the provisions of Section 16 of the Act, except in regard to Cases No. 04-135-I-29 and 00-135-I-18, 97-8-RI-2, 82-26-I-98, CI-87-8-151 (82-26-I-98) and 74-57-I-89, in which the application of Section 16 is waived, and the use of previously exempt facilities, land, buildings, machinery and equipment, inventory, supplies, trademarks, and marketing outlets utilized by the Grantees is approved;

BE IT FURTHER DECREED, that the tax benefits Granted herein shall be applicable only to the property directly used in connection with the production of the manufactured products or the rendering of the services hereinbefore listed and the fixed tax rate to the industrial development income (as defined in the Act) derived from the production of said manufactured products and/or the rendering of the services listed which give rise to the exemption provided by this decree, and such other property specifically declared exempt by the Act;

BE IT FURTHER DECREED, that the Grantees shall comply with all requirements imposed by the Environmental Assessment Report of the Environmental Affairs Office of the Industrial Development Company (Exhibit I);

BE IT FURTHER DECREED, that the continuance of this Grant shall be conditional upon compliance by the Grantees with such regulations and requirements as the Environmental Quality Board of the Commonwealth of Puerto Rico has heretofore promulgated and may hereafter promulgate, relative to the control of water, air, ground and any other environmental pollution; PROVIDED, FURTHER, that Grantees shall obtain all permits applicable to its operations from the Regulations and Permits Administration (RPA) and the Puerto Rico Planning Board;

BE IT FURTHER DECREED, that said tax benefits shall include exemption to the extent provided in the Act from all Commonwealth taxes, and from license fees and other municipal taxes levied by any ordinance of any municipality, except as otherwise hereinbefore provided in this Decree;

BE IT FURTHER DECREED, that there shall be excluded from the scope of the benefits of this Grant the operation of retail stores; and the providing of any services in connection with the sales of the manufactured products;

BE IT FURTHER DECREED, that the Grantees shall make all possible efforts to buy from local enterprises the products, services, materials, components, equipment and machinery available in Puerto Rico, that are necessary for its operations; the Grantees shall annually demonstrate to the Office of Industrial Tax Exemption the measures taken to increase their local purchases from other manufacturers or distributors in the island;

BE IT FURTHER DECREED, that the Grant shall not include exemption from:

- a. Workmen's compensation premiums as provided by law;
- b. Fees for motor vehicle licenses or plates;
- c. Taxes levied under Act No. 286, of April 6, 1946;

BE IT FURTHER DECREED, that as a condition to the continuance of the tax benefits hereby Granted the Grantees shall be required, in conformance with Section 18 of the Act, to file with the Secretary of the Treasury of the Commonwealth of Puerto Rico ("Secretary of the Treasury"), regardless of its gross or net income, an annual income tax return, separate from any other return it is required to file, in relation to the business operations covered by this Grant and in accordance with the Puerto Rico Internal Revenue Code of 1994, as amended (the "Code"), as amended; the exempted business shall also be required to keep in Puerto Rico the accounting records relative to its operations separately, as well as the necessary records and files, and to

make and submit such sworn statements, and comply with the rules and regulations in force for the proper fulfillment of the purposes under the Code and that the Secretary of the Treasury may prescribe from time to time in connection with the levying and collection of all kinds of taxes; every exempted business shall file duly completed reports and surveys for the preparations of statistics and economic studies that may be requested by the Executive Director of the Puerto Rico Industrial Development Company in the performance of his duties; provided, further, that the Grantees shall file duly completed reports that may be requested by the Office of the Commissioner of Financial Institutions;

BE IT FURTHER DECREED, that the Grantees shall comply with the obligations set pursuant Section 18 (d) of the Act, to submit an annual report to the Office of Industrial Tax Exemption, with copies to the Secretary of the Treasury and the Executive Director of the Puerto Rico Industrial Development Company, within the time limit of thirty (30) days after the date provided by law to submit income tax returns, including any extensions; PROVIDED that not compliance with this obligation can expose Grantees to fines and/or other administrative sanctions as the revocation of the Grant approved;

BE IT FURTHER DECREED, that the Executive Director of the Municipal Revenue Collection Center (MRCC) and the Secretary of the Treasury shall determine for each taxable year covered by this exemption what property and what income the Grantees has used in, or derived from the industrial operations hereby declared tax exempt; PROVIDED, that nothing contained herein shall deprive the Grantees of its right to administrative and judicial review of such determinations of the Executive Director of the MRCC and the Secretary of the Treasury available by Constitution, Law or Regulation;

BE IT FURTHER DECREED, that the Executive Director of the MRCC and the Secretary of the Treasury, in determining what property has been used in and what income has been derived from the industrial operations of the Grantees hereby declared tax exempt, may review the accounts and records of the Grantees to determine that all purchase prices, sales prices, rates of lease, overhead or any other cost allocations, and all other prices, rates, and cost allocations are fixed on the basis of normal business operations and not for the purposes of avoiding taxes ordinarily chargeable to activities not within the scope of the industrial operations covered by this Grant or of charging to the operations carried on outside of Puerto Rico; PROVIDED, that whenever it is found that such rates or charges are made for the purposes of extending the coverage of the Grant beyond the scope of the covered operations reasonable adjustments shall be made for the purpose of calculating the amount of taxes payable by the Grantees, if any, and shall make such recommendations to the Secretary of the Department of Economic Development and Commerce as to such other action as may be taken under the provisions of Section 13 of the Act and the Rules and Regulations promulgated hereunder; PROVIDED, that nothing contained herein shall deprive the Grantees of its right to administrative and judicial review of such determination of the Executive Director of the MRCC and the Secretary of the Treasury available by Constitution, Law or Regulation;


BE IT FURTHER DECREED, that Grantees must comply with all the laws, rules, regulations, orders and ordinances promulgated by the Commonwealth of Puerto Rico, its agencies and municipalities which are applicable to Grantees' operations, including all the provisions of Act No. 73, which are applicable to Grantees, and all rules and regulations promulgated pursuant to the Act, regardless of whether or not said provisions are specifically mentioned in this Grant;

BE IT FURTHER DECREED, that the Grantees must pay or clarify any possible income tax debt, employee withholding income tax and any other debt notified by the Department of the Treasury of the Commonwealth of Puerto Rico. Otherwise, the Grant could be temporarily or permanently revoked;

BE IT FURTHER DECREED, that upon its acceptance by Grantees, this Grant constitutes a contract between the Commonwealth of Puerto Rico and the Grantees, its shareholders, partners or owners, and said Contract will be the law between the parties involved. Said Contract will be interpreted liberally, pursuant to the purposes of the Act of promoting the economic and social development of Puerto Rico. The Secretary of the Department of Economic Development and Commerce has the discretion to include, in the name and in representation of the Government of Puerto Rico, all the terms and conditions, concessions and exemptions that are consistent with the purpose of this Law and that promote the creation of jobs through the economic and social development of Puerto Rico, taking into consideration the nature of the application or the request submitted including the facts and other related circumstances with respect each case in particular that could be applicable;

BE IT FURTHER DECREED, that this Grant shall become retroactively null and void unless the Grantees shall file with the Office of Industrial Tax Exemption, within ninety (90) days after the receipt of this Grant by the Grantees, a duly notarized and sworn declaration wherein the Grantees expresses its unconditional acceptance of this Grant and of all the conditions, provisions, and findings which are an integral part hereof;

BE IT FURTHER DECREED, that upon receipt of this Grant, the Director of the Office of Industrial Tax Exemption shall immediately forward a copy to the Grantees.

  
JOSE R. PÉREZ RIERA  
SECRETARY OF THE DEPARTMENT  
OF ECONOMIC DEVELOPMENT AND  
COMMERCE

DEC 23 2009

**Schedule 1.1(y)**  
**Buyer Parent Knowledge**

Eyal Desheh  
David Stark

LA\_LAN01:284952.6

**Schedule 1.1(z)**  
**Draft Debt Commitment Letter**

The draft debt commitment letter from Bank of America Merrill Lynch International Limited, Bank of America N.A., London Branch, Barclays Bank PLC, BNP Paribas Fortis SA/NV, Citibank, N.A., Credit Suisse AG, Cayman Islands Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Royal Bank of Canada and Sumitomo Mitsui Banking Corporation Banking Corporation provided to Seller Parent on July 26, 2015 shall be deemed to be customary for similar acquisition financings (except for the provisions contemplating the investment grade condition and a termination date that is earlier than the termination date in the Agreement), and all such banks and institutions shall be acceptable.

**Schedule 2.1(b)(vii) – Patents, Licensed Patents, Marks and Licensed Marks**



Pharmaceutical Product	Title	Country	Filing Date	Appl. No.	Status	Patent No.	Approximate Expiration Date	Owner
Aminophylline formulations	Bronchodilatation Medicamentous Form	BG	16/12/1998	BG103023	Granted	BG63965	16/12/2018	Balkanpharma Dupnitza AD
Aspartate formulations	Film-tablet Form of Active Potassium and Magnesium DL-Aspartate Substance and Method for its Preparation	BG	28/01/1999	BG 103125	Pending	BG64373	28/02/2019	Balkanpharma Dupnitza AD
Atomoxetine Formulations	Atomoxetine Formulations	DE	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Atomoxetine Formulations	Atomoxetine Formulations	EP	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Atomoxetine Formulations	Atomoxetine Formulations	ES	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Atomoxetine Formulations	Atomoxetine Formulations	FR	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Atomoxetine Formulations	Atomoxetine Formulations	GB	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Atomoxetine Formulations	Atomoxetine Formulations	IT	23/12/2004	04815693.9	Granted	EP1715856	23/12/2024	Actavis Group PTC ehf
Ciprofloxacin formulations	Composition And Method For The Preparation Of A Medicamentous Form	BG	09/09/1998	BG102756	Granted	BG63287	09/09/2018	Balkanpharma Dupnitza AD
Conjugated estrogens	Compositions For Conjugated Estrogens And Associated Methods	CA	8/27/2004	2,539,872	Granted	2,539,872	August 2024	Watson Laboratories, Inc.
Conjugated estrogens	Compositions For Conjugated Estrogens And	EP	8/27/2004	04782556.7	Granted	1,689,372	August 2024	Watson Laboratories, Inc.

	Associated Methods							
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	CA	2/8/2002	2,443,915	Granted	2,433,915	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	CA	2/8/2002	2,685,214	Granted	2685214	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	US	2/8/2001	09/905,712	Granted	6,589,553	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	US	2/8/2002	10/071,257	Granted	8,545,880	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	US	5/9/2003	10/435,012	Granted	6,905,708	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	US	3/1/2005	11/069,435	Granted	7,771,750	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Improved Controlled Release Oral Dosage Form	US	7/14/2010	12/835,863	Granted	8,747,898	February 2019	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Stable Pharmaceutical Composition Without Stabilizers	US	11/21/2002	10/301,474	Granted	6,893,660	December 2022	Andrx Pharmaceuticals, LLC
Controlled-release bupropion	Stable Pharmaceutical Composition Without Stabilizers	US	1/3/2005	11/028,391	Granted	8,501,227	December 2022	Andrx Pharmaceuticals, LLC

Controlled-release diltiazem	Two Pellet Controlled Release Formulation For Water Soluble Drugs Which Contains An Alkaline Metal Stearate	CA	11/1/1999	2,349,696	Granted	2,349,696	November 2019	Andrx Pharmaceutica Is, LLC
Controlled-release diltiazem	Diltiazem Controlled Release Formulation and Method of Manufacture	CA	7/16/1999	2,338,070	Granted	2,338,070	July 2019	Andrx Pharmaceutica Is, LLC
Controlled-release diltiazem	Diltiazem Controlled Release Formulation And Method Of Manufacture	CA	8/10/2006	2,617,351	Granted	2,617,351	August 2026	Watson Pharmaceutica Is, Inc. (n/k/a Actavis, Inc.)
Controlled-release diltiazem	Diltiazem Controlled Release Formulation And Method Of Manufacture	EPO	8/10/2006	6801043.8	Pending			Watson Pharmaceutica Is, Inc. (n/k/a Actavis, Inc.)
Controlled-release diltiazem	Two Pellet Controlled Release Formulation For Water Soluble Drugs Which Contains An Alkaline Metal Stearate	NZ	11/1/1999	511448	Granted	511448	November 2019	Andrx Pharmaceutica Is, LLC
Controlled-release diltiazem	Two Pellet Controlled Release Formulation For Water Soluble Drugs Which Contains An Alkaline Metal	US	11/6/1998	09/187319	Granted	6,270,805	November 2018	Andrx Pharmaceutica Is, LLC

	Stearate							
Controlled-release diltiazem	Diltiazem Controlled Release Formulation and Method of Manufacture	US	7/20/1998	09/119,323	Granted	6,524,620	July 2018	Andrx Pharmaceuticals, LLC
Controlled-release diltiazem	Diltiazem Controlled Release Formulation And Method Of Manufacture	US	8/11/2005	11/201,747	Granted	8,778,395	October 2029	Andrx Labs, LLC
Controlled-release hydrocodone and acetaminophen	Controlled Release Formulations and Associated Methods	CA	7/19/2007	2,657,913	Pending			Watson Laboratories, Inc.
Controlled-release hydrocodone and acetaminophen	Controlled Release Formulations and Associated Methods	JP	7/19/2007	2009-520861	Pending			Watson Laboratories, Inc.
Controlled-release hydrocodone and acetaminophen	Controlled Release Formulations and Associated Methods	NZ	7/19/2007	574325	Granted	574325	July 2027	Watson Laboratories, Inc.
Controlled-release hydrocodone and acetaminophen	Controlled Release Formulations and Associated Methods	US	7/19/2006	11/458,651	Granted	8,765,178	February 2029	Watson Laboratories, Inc.
Controlled-release Ketoprofen	Controlled Release Oral Dosage Form	US	6/29/1998	09/106,609	Granted	6,197,347	June 2018	Andrx Pharmaceuticals, LLC
Controlled-release Ketoprofen	Controlled Release Oral Dosage Form	US	8/11/2000	09/637,404	Granted	6,238,703		Andrx Pharmaceuticals, LLC



Controlled-release methylphenidate	Oral Controlled Release Dosage Form	US	12/2/2003	10/726,024	Granted	7,988,993	February 2026	Andrx Pharmaceutica ls, Inc.
Controlled-release methylphenidate	Oral Controlled Release Dosage Form	US	7/11/2011	13/179,830	Granted	8,252,327	December 2023	Andrx Pharmaceutica ls, Inc.
Controlled-release methylphenidate	Oral Controlled Release Dosage Form	US	8/20/2012	13/590,061	Pending			Andrx Pharmaceutica ls, Inc.
Controlled-release Zolpidem	Oral Controlled Release Formulation For Sedative And Hypnotic Agents	CN	3/1/2007	200780007189.5	To be abandoned			Watson Pharmaceutica ls, Inc. (n/k/a Actavis, Inc.)
Controlled-release Zolpidem	Oral Controlled Release Formulation For Sedative And Hypnotic Agents	IN	3/1/2007	3270/KOL NP/2008	To be abandoned			Watson Pharmaceutica ls, Inc. (n/k/a Actavis, Inc.)
Controlled-release Zolpidem	Oral Controlled Release Formulation For Sedative And Hypnotic Agents	JP	3/1/2007	2008-557414	To be abandoned			Watson Pharmaceutica ls, Inc. (n/k/a Actavis, Inc.)
Controlled-release Zolpidem	Oral Controlled Release Formulation For Sedative And Hypnotic Agents	US	2/28/2007	11/712,133	Granted	8,309,104	February 2029	Watson Pharmaceutica ls, Inc. (n/k/a Actavis, Inc.)
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	BR	8/14/2006	PI 061.4279-6	Pending			Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	BR	2/14/2008	PI 061.4280-0	Pending			Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co.

								Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	CA	8/14/2006	2,619,486	Pending			Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	CA	8/14/2006	2,619,040	Granted	2,619,040	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	CN	8/14/2006	200680034164.X	Granted	ZL 200680034164. X	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	EP	8/14/2006	06765276.8	Granted	1928823	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	EP	8/14/2006	06765284.2	Granted	1924555	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.

Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	NZ	2/27/2008	566286	Granted	566286	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	NZ	2/27/2008	566287	Granted	566287	August 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	US	8/15/2006	11/504,104	Granted	8,097,734	February 2028	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	US	12/13/2011	13/324,678	Granted	8,329,922	September 2026	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	US	8/15/2006	11/504,103	Granted	8,017,647	June 2027	Arrow International Limited co-owner with Zhejiang Neo-Dankong Pharm. Co. Ltd.
Crystalline Sodium Atorvastatin	Crystalline Sodium Atorvastatin	US	5/20/2011	13/112,377	Granted	8,440,712	August 2026	Arrow International Limited co-owner with

								Zhejiang Neo-Dankong Pharm. Co. Ltd.
Delayed-release medicines	Solid Batched Medicamentous Forms Of Delayed Release	BG	07/06/1996	BG100651	Granted	BG62717	07/01/2016	Balkanpharma Dupnitza AD
Delayed-release nifedipine	Once Daily Calcium Channel Blocker Having A Delayed Release Core	US	1/31/1997	08/792,001	Granted	5,922,352	January 2017	Andrx Pharmaceutica Is, Inc.
Delayed-Release Pseudoephedrine	Antihistamine and Decongestant System	US	11/8/2002	10/291,103	Granted	8,092,831	October 2026	Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	CA	6/16/2004	2,673,334	Granted	2,673,334	June 2024	Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	CA	6/16/2004	2,675,724	Granted	2,675,724	June 2024	Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	CA	6/16/2004	2,529,746	Granted	2,529,746	June 2024	Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	EP	6/16/2004	12176084.7	Pending			Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	EP	6/16/2004	12176088.8	Pending			Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	EP	6/16/2004	4776663.9	Pending			Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	US	10/16/2004	10/869,497	Granted	7,476,403	December 2025	Andrx Pharmaceutica Is, LLC
Extended-release clarithromycin	Oral Extended-Release Composition	US	12/3/2008	12/327,477	Granted	8,628,797	December 2025	Andrx Pharmaceutica Is, LLC



Extended-release diltiazem	Enteric Coated Diltiazem Once-A-Day Formulation	US	6/21/1996	08/667,308	Granted	5,830,503	November 2016	Andrx Pharmaceuticals, LLC
Extended-release metoprolol succinate	Formulation and Process for Drug Loaded Cores	US	7/11/2003	10/617,456	Granted	7,314,640	July 2025	Andrx Pharmaceuticals, LLC
Extended-release metoprolol succinate	Formulation and Process for Drug Loaded Cores	US	10/19/2007	11/975,519	Granted	7,790,200	July 2023	Andrx Pharmaceuticals, LLC
Extended-release metoprolol succinate	Formulation and Process for Drug Loaded Cores	US	8/10/2010	12/853,820	Pending			Andrx Pharmaceuticals, LLC
Extended-release venlafaxine	Extended Release Venlafaxine Formulation	HK	10/29/2004	10111018.3	Pending			Andrx Pharmaceuticals, LLC
Extended-release venlafaxine	Extended Release Venlafaxine Formulation	US	11/17/2003	10/715,219	Granted	7,470,435	December 2025	Andrx Pharmaceuticals, LLC
Extended-release venlafaxine	Extended Release Venlafaxine Formulation	US	11/17/2003	12/313,340	Granted	7,931,915	November 2023	Andrx Pharmaceuticals, LLC
Extended-release venlafaxine	Extended Release Venlafaxine Formulation	US	3/18/2011	13/051,076	Granted	8,668,932	November 2024	Andrx Pharmaceuticals, LLC
Finasteride Formulations	Formulations Of Finasteride	EP	21/11/2003	03811862.6	Pending	-	-	Actavis Group hf
Finasteride Formulations	Formulations Of Finasteride	IS	21/11/2003	7888	Pending	-	-	Actavis Group hf
Gabapentin prodrug	Gabapentin Prodrugs and Formulations	US	10/23/2001	10/040,251	Granted	6,683,112	November 2021	Andrx Corporation
Lansoprazole Amine Salt	Stable R(+)-Lansoprazole Amine Salt and a Process For Preparing The	BR	5/12/2009	PI 0912478-0	Pending			Watson Pharma Private Limited

	Same							
Lansoprazole Amine Salt	Stable R(+)-Lansoprazole Amine Salt and a Process For Preparing The Same	NZ	5/12/2009	589150	Granted	589150	May 2029	Watson Pharma Private Limited
Lansoprazole Amine Salt	Stable R(+)-Lansoprazole Amine Salt and a Process For Preparing The Same	US	11/10/2010	12/992,034	Granted	8,362,042	May 2029	Watson Pharma Private Limited
Lansoprazole Amine Salt	Stable R(+)-Lansoprazole Amine Salt and a Process For Preparing The Same	ZA	5/12/2009	2010/08188	Granted	2010/08188	May 2029	Watson Pharma Private Limited
Laquinamod polymorphs	Highly Pure Laquinimod Or A Pharmaceutically Acceptable Salt Thereof	IN	17/12/2008	3167/CHE/2008	Pending	-	-	Actavis Group PTC ehf
Laquinamod polymorphs	Highly Pure Laquinimod Or A Pharmaceutically Acceptable Salt Thereof	US	15/12/2009	13/603,554	Pending	-	-	Actavis Group PTC ehf
Laquinimod Polymorphs	Novel Solid State Forms Of Laquinimod And Its Sodium Salt	US	30/06/2009	13/001,715	Granted	8,354,428	30/06/2029	Actavis Group PTC ehf
Linezolid formulations	-	IS	29/01/2013	050044	Pending	-	-	Actavis Group PTC ehf
Loratadine	Rapidly Disintegrating Antihistamine Formulation	US	9/28/2004	10/951,737	Granted	8,529,946	May 2028	Andrx Pharmaceuticals, LLC

Modified-release tranexamic acid	Modified Release Tranexamic Acid Formulation	US	11/30/2010	12/956,036	Granted	8,597,683	October 2031	Watson Pharmaceuticals, Inc. (n/k/a Actavis, Inc.)
Modified-release tranexamic acid	Modified Release Tranexamic Acid Formulation	US	11/19/2013	14/083,563	Pending			Watson Pharmaceuticals, Inc. (n/k/a Actavis, Inc.)
Nicotine chewing gum	Stabilized Nicotine Chewing Gum	AU	11/24/2009	2009324945	Pending			Watson Laboratories, Inc.
Nicotine chewing gum	Stabilized Nicotine Chewing Gum	BR	11/24/2009	PI0915256-3	Pending			Watson Laboratories, Inc.
Nicotine chewing gum	Stabilized Nicotine Chewing Gum	CA	11/24/2009	2,742,373	Pending			Watson Laboratories, Inc.
Nicotine chewing gum	Stabilized Nicotine Chewing Gum	US	11/25/2008	12/277,590	Granted	8,506,936	January 2030	Watson Laboratories, Inc.
Olanzapine formulations	Rapidly Disintegrating Dosage Form Comprising Magnesium Carbonate Heavy	DE	02/03/2006	06711375.3	Granted	1863443	02/03/2026	Actavis Group PTC ehf
Olanzapine formulations	A Pharmaceutical Formulation Containing Olanzapine	DE	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf
Olanzapine formulations	Rapidly Disintegrating Dosage Form Comprising Magnesium Carbonate Heavy	EP	02/03/2006	06711375.3	Granted	1863443	02/03/2026	Actavis Group PTC ehf
Olanzapine formulations	A Pharmaceutical Formulation	EP	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf

	Containing Olanzapine							
Olanzapine formulations	A Pharmaceutical Formulation Containing Olanzapine	ES	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf
Olanzapine formulations	Rapidly Disintegrating Dosage Form Comprising Magnesium Carbonate Heavy	FR	02/03/2006	06711375.3	Granted	1863443	02/03/2026	Actavis Group PTC ehf
Olanzapine formulations	A Pharmaceutical Formulation Containing Olanzapine	FR	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf
Olanzapine formulations	Rapidly Disintegrating Dosage Form Comprising Magnesium Carbonate Heavy	GB	02/03/2006	06711375.3	Granted	1863443	02/03/2026	Actavis Group PTC ehf
Olanzapine formulations	A Pharmaceutical Formulation Containing Olanzapine	GB	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf
Olanzapine formulations	A Pharmaceutical Formulation Containing Olanzapine	IT	27/10/2006	06831860.9	Granted	EP1928428	27/10/2026	Actavis Group PTC ehf
Omeprazole	Omeprazole Formulation	US	11/14/1997	08/970,489	Granted	6,096,340	November 2017	Andrx Pharmaceutica ls, LLC
Omeprazole	Omeprazole Formulation	US	6/18/1999	09/335,575	Granted	6,077,541	November 2017	Andrx Pharmaceutica ls, LLC
Omeprazole	Omeprazole Formulation	US	10/23/2002	10/279,622	Granted	6,780,435	Novmeber 2017	Andrx Pharmaceutica



								Is, LLC
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	AU	5/19/2006	2006248745	Granted	2006248745	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	BR	5/19/2006	PI 0609632-8	Pending			Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	CA	5/19/2006	2,608,490	Granted	2,608,490	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	CN	5/19/2006	200680017571.X	Granted	CN101233134B	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	EP	5/19/2006	06743955.4	Granted	1,883,639	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.

Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	JP	5/19/2006	2008-511798	Granted	5227166	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	NZ	5/19/2006	563636	Granted	563636	May 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	TW	5/19/2006	9117840	Pending			Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing famciclovir	Preparation of Famciclovir and Other Purine Derivatives	US	11/10/2005	11/270,777	Granted	7,601,835	July 2026	Arrow International Limited co-owner with Chongqing Shenghuaxi Pharmaceutica I Co., Ltd.
Process for preparing lansoprazole	A Process for Preparation of Stable Amorphous R-Lansoprazole	BR	12/18/2008		Pending			Watson Pharma Private Limited
Process for preparing lansoprazole	A Process for Preparation of Stable Amorphous R-Lansoprazole	NZ	12/18/2008	585944	Granted	585944	December 2028	Watson Pharma Private Limited
Process for preparing	Improved Process For	EP	27/04/2009	09738481.2	Pending	-	-	Actavis Group PTC ehf

Laquinimod	Preparing Quinoline-3-Carboxamide Derivatives							
Process for preparing Laquinimod	Improved Process For Preparing Quinoline-3-Carboxamide Derivatives	IN	28/04/2008	1041/CHE/2008	Pending	-	-	Actavis Group PTC ehf
Process for preparing Laquinimod	Improved Process For Preparing Quinoline-3-Carboxamide Derivatives	US	27/04/2009	12/989,796	Granted	8,552,194	27/04/2029	Actavis Group PTC ehf
Process for preparing Laquinimod	Improved Process For Preparing Quinoline-3-Carboxamide Derivatives	US	27/04/2009	14/020,941	Pending	-	-	Actavis Group PTC ehf
Process for preparing paliperidone	An Improved Process For Preparation Of Paliperidone	NZ	2/5/2009	586930	Granted	586930	February 2019	Watson Pharma Private Limited
Pseudoephedrine Combination Pharmaceutical Compositions	A Pharmaceutical Tablet Composition For Oral Administration Containing Pseudoephedrine Pellets Admixed With A Tablet Mixture Containing A Second Active Drug Substance, Either Alone Or In Combination With	US	14/11/1996	08/746,666	Granted	5,807,579	14/11/2016	Actavis Elizabeth LLC

	Pseudoephedrine Or A Pharmaceutically Acceptable Salt Thereof, Is Disclosed. The Pellets Provide An Extended Release Of Pseudoephedrine, Whereas The Tablet Mixture Provides An Immediate Release Of The Second Active Drug And Any Pseudoephedrine.							
Rasagiline formulations	-	PCT	06/06/2013	PCT/EP2013/061646	Pending	-	-	Actavis Group PTC ehf
Rasagiline Particles	Rasagiline Mesylate Particles And Process And Process For Preparation Thereof.	EP	31/03/2009	09726618.3	Pending	-	-	Actavis Group PTC ehf
Sustained-release tramadol	Controlled Release Oral Dosage Form	US	5/26/1998	09/084,622	Granted	6,156,342	May 2018	Andrx Pharmaceuticals, Inc.
Tapentadol Polymorphs	Solid State Forms Of Tapentadol Salts	US	21/09/2010	12/886,680	Granted	8,288,592	21/09/2030	Actavis Group PTC ehf
Tapentadol Polymorphs	Solid State Forms Of Tapentadol Salts	US	21/09/2010	13/609,661	Pending	-	-	Actavis Group PTC ehf
Tetracycline Salts	Drug Salts	US	13/03/1995	08/402,619	Granted	6,077,822	20/06/2017	Actavis Group hf



Tocopherol formulations	Tocopherol Compositions For Delivery Of Biologically Active Agents	NZ	15/05/1995	287857	Granted	287857	15/05/2015	Dumex-Alpha A/S
Tocopherol formulations	Tocopherol Compositions For Delivery Of Biologically Active Agents	US	16/05/1995	08/856,054	Granted	6,193,985	27/02/2018	Actavis Group hf
Usnic Acid Disinfectant	Usnic Acid Disinfectant	BA	03/11/2000	BAP021296A	Granted	BAP021296B	03/11/2020	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	EA	03/11/2000	200300021/28	Granted	EAP0006582	03/11/2020	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	EP	03/11/2000	00974145.5	Granted	EP1294373	03/11/2020	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	MD	03/11/2000	200300021/28	Granted	EAP0006582	03/11/2020	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	MK	03/11/2000	00974145.5	Granted	MK901168	03/11/2020	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	RO	03/11/2000	00974145.5	Granted	RO/EP1294373	03/11/2015	Zdravlje AD
Usnic Acid Disinfectant	Usnic Acid Disinfectant	RS	15/06/2000	P-373-2000	Granted	49778	15/06/2020	Zdravlje AD

**Schedule 2.1(b)(xxi)– List of Assets**

None.

**Schedule 2.2(i) – Excluded Assets**

- Generic Drugs sold by the Allergan Business (including Seller Parent's ophthalmic business).
- Any assets obtained under that certain Collaboration Agreement, dated December 19, 2011, by and between Amgen Inc. and Watson Laboratories, Inc.
- Trademarks not used in connection with any launched product and which are owned by Actavis, Inc., Actavis Group PTC ehf, or Actavis Group ehf.
- Intellectual Property relating to the formulation or composition of Manufactured Products (as defined in the Term Sheet for the Manufacturing Agreement set out as Exhibit B to the Agreement) which are to be manufactured by the Buyer Group pursuant to the Manufacturing Agreement.
- All Intellectual Property owned by the Seller Group and not Related to the Business.
- The patents shown on the workbook in the excel file entitled "Project Trump - Excluded Assets\_Patents 7 26 15.xlsx", the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark at Latham & Watkins at 03.04 AM on July 27, 2015, solely with respect to patents that do not cover, or otherwise relate to, any Generic Drugs (other than the Retained Business).
- Rights to any regulatory applications or development projects related to lifecycle products for the Retained Business. Lifecycle products may include new formulations, product combinations, or dosage forms that contain the same active ingredient(s) as a pharmaceutical product in the Retained Business, and are intended to be promoted by the Retained Business (not to be sold as Generic Drugs).
- License Agreement between Merck Sharp & Dohme Corp. and Seller Group dated as of July 6, 2015.
- Agreement and Plan of Merger among Actavis, Inc., Wolverine Merger Sub, Inc., Oculeve, Inc. and Fortis Advisors LLC, as Shareholders' Representative, dated as of July 5, 2015.
- Transfer Asset Purchase Agreement and Development Provisions between Rugen Holdings (Cayman) Limited and Seller Group dated as of May 1, 2015, and any related Intellectual Property.
- Collaboration Agreement between Amgen, Inc. and Watson Laboratories, Inc. dated as of December 19, 2011, and any related Intellectual Property .
- License and Development Agreement, dated as of July 14, 2010, by and between Itero Biopharmaceuticals, Inc. and Arrow International Ltd.
- Excluded Manufacturing Facilities:

- Weiterstadt, Germany
- Liege, Belgium

**Schedule 2.3 – Assumed Liabilities**

- Any Liabilities in connection with the generic Opana ER patent infringement litigations (Endo Pharms. Inc. et al. v. Actavis Inc. et al., Case Nos. 12-cv-8985-Griesa (S.D.N.Y.); 14-cv-01381 – Andrews (D. Del.))
- Any Liabilities in connection with the generic Lysteda patent infringement litigation (Ferring B.V. v. Actavis, Inc. et al. 2:15-cv-04222-KSH-CLW (D.N.J.))
- Any Liabilities in connection with the generic Opana ER false advertising litigation (Endo Pharms. Inc. v. Actavis, Inc., Case No. 2:12-cv-07591-KM-SCM (D.N.J.))
- Any Liabilities in connection with the generic Valsartan patent proceedings in EU.
- Any Liabilities in connection with the generic Aripiprazole patent proceedings in EU.
- Any Liabilities, to the extent Related to the Business, in connection with the litigation shown in the Excel file entitled “TRUMP-Commercial Litigation Log.xlsx”, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark at Latham & Watkins at 03.04 AM on July 27, 2015.

**Schedule 2.4(h) – Excluded Liabilities**

None.

Schedule 4.3 – Reports and Financial Information

Schedule 4.3 - Unaudited Performance Financial Statements of the Business for the year ending December 31, 2014			
USD in millions	USGx Business	Int'l Business	Total Business
Product sales	4,002	2,415	6,417
Other revenue	32	83	115
<b>Net revenue</b>	<b>4,033</b>	<b>2,499</b>	<b>6,532</b>
Cost of sales	(1,582)	(1,261)	(2,843)
<b>Gross profit</b>	<b>2,452</b>	<b>1,237</b>	<b>3,689</b>
Sales and Marketing expenses	(70)	(548)	(618)
Research and Development expenses	(254)	(211)	(465)
General and Administrative expenses	(351)	(266)	(617)
<b>Operating expenses</b>	<b>(675)</b>	<b>(1,025)</b>	<b>(1,700)</b>
<b>Contribution</b>	<b>1,777</b>	<b>212</b>	<b>1,989</b>
Depreciation			151
<b>EBITDA</b>			

			2,140
<b>Notes</b>			
<i>1) The Performance Financial Statements EXCLUDE:</i>			
a) Items considered to be of a non-GAAP nature by Allergan plc, all determined on a basis consistent with its non-GAAP presentation as part of quarterly and year-end press releases and reporting. Items excluded consist of of 1) global supply chain initiative, 2) acquisition and licensing and other charges, 3) impairment / asset sales and related costs, 4) non-recurring losses and gains, 5) legal settlements, 6) accretion on contingent liabilities and 7) share based compensation.			
b) Depreciation for the Forest and Aptalis business for the 6 months ending December 31, 2014			
c) The results for the Western-European assets that were sold to Aurobindo Pharma Limited effective April 1, 2014. These assets included the commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights			
d) The results of Auden McKenzie which was acquired by Allergan plc effective June 1, 2015. For the avoidance of the doubt, Auden McKenzie will be part of the Business			
2) The Performance Financial Statements include the international Forest results that will be part of the Business for 6 months only, following the transaction close at July 1, 2014			
3) For the avoidance of doubt, the results of certain manufacturing plants and contract manufacturing agreements within the Aptalis Pharmaceutical Technologies ("Pharmatech") entities that were disposed to TPG in 2015 are included in the above Performance Financial Statements			



**Schedule 4.6(c) – Transferred Group**

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
1. Warner Chilcott Company, LLC	Puerto Rico
2. Warner Chilcott (Ireland) Limited	Ireland
3. Warner Chilcott Finance LLC.	Delaware
4. Warner Chilcott Australia Pty. Ltd.	Australia
5. Warner Chilcott Pharmaceuticals B.V.B.A.	Belgium
6. Warner Chilcott France SAS	France
7. Warner Chilcott Italy S.r.l.	Italy
8. Actavis Pharma Iberia S.L. (f/k/a Warner Chilcott Iberia S.L.)	Spain
9. Robin Hood Holdings Ltd.	Malta
10. Paomar plc	Cyprus
11. Actavis Pharma Pty Ltd.	Australia
12. Makoff R&D Laboratories, Inc.	California
13. R&D Pharmaceutical, Inc.	California
14. R&D Ferriecit Capital Resources, Inc.	California
15. R&D Research & Development Corp.	California
16. R&D New Media Services, Inc.	California
17. Royce Laboratories, Inc.	Florida
18. Royce Research Group, Inc.	Florida
19. Royce Research & Development Limited Partnership I	Florida
20. The Rugby Group, Inc.	New York
21. Watson Laboratories, Inc. Ohio	New York

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
22. Rugby Laboratories, Inc.	New York
23. Changzhou Siyao Pharmaceuticals Co., Ltd.	China
24. Watson Pharmaceuticals (Asia) Ltd.	BVI
25. WP Holdings, Ltd.	BVI
26. Watson Pharmaceuticals, China Ltd	BVI
27. Med All Enterprise Consulting (Shanghai) Co. Ltd.	China
28. Nicobrand Limited	Northern Ireland
29. Watson Pharmaceuticals International Ltd.	BVI
30. Watson Diagnostics, Inc.	Delaware
31. Del Mar Indemnity Co. Inc.	Hawaii
32. Actavis Laboratories NY, Inc.	New York
33. Circa Pharmaceuticals West, Inc.	California
34. Circa Sub	New York
35. Andrx Corporation	Delaware
36. Andrx South Carolina I, Inc.	South Carolina
37. Andrx Pharmaceuticals (Mass), Inc.	Florida
38. Andrx Pharmaceuticals Equipment #1, LLC	Florida
39. Andrx Pharmaceuticals (NC) Inc.	Florida
40. Andrx Pharmaceuticals, (NC) Equipment LLC	Delaware
41. SR Six, Inc.	Florida
42. Ancirc Pharmaceuticals	New York
43. RxAPS, Inc.	Florida
44. Andrx Pharmaceuticals Sales and Marketing, Inc.	Florida

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
45. Actavis Laboratories FL, Inc.	Florida
46. Watson Management Corporation	Florida
47. Watson Therapeutics, Inc.	Florida
48. Valmed Pharmaceuticals, Inc.	New York
49. Andrx Pharmaceuticals, LLC	Delaware
50. Andrx Labs LLC	Delaware
51. Andrx Laboratories (NJ) Inc.	Delaware
52. Watson Cobalt Holdings, LLC	Delaware
53. Watson Manufacturing Services, Inc.	Delaware
54. Natrapac, Inc.	Utah
55. Coventry Acquisition, LLC	Delaware
56. Cobalt Laboratories, LLC	Delaware
57. Watson Pharma Private Ltd.	India
58. Watson Laboratories, LLC	Delaware
59. Actavis Puerto Rico Holdings Inc.	Delaware
60. Actavis US Holding LLC	Delaware
61. Actavis LLC	Delaware
62. Actavis South Atlantic LLC	Delaware
63. Actavis Elizabeth LLC	Delaware
64. Actavis Kadian LLC	Delaware
65. Actavis Mid Atlantic LLC	Delaware
66. Actavis Totowa LLC	Delaware
67. Actavis Pharmaceuticals NJ, Inc.	Delaware

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
68. Watson Laboratories, Inc.	Connecticut
69. Watson Laboratories, Inc.	Delaware
70. Schein Bayer Pharmaceutical Services, Inc.	Delaware
71. Schein Pharmaceutical International, Inc.	Delaware
72. Schein Pharmaceutical Ltd	Bermuda
73. Marsam Pharma, LLC	Delaware
74. MSI, Inc.	Delaware
75. Actavis Holding 2 Sàrl	Luxembourg
76. Actavis Services (Asia) Ltd.	Malta
77. Arrow Laboratories, Ltd.	Malta
78. Arrow Supplies, Ltd.	-
79. Arrow Pharma HK Ltd.	Hong Kong
80. Marrow Pharmaceuticals Research & Development Co Ltd.	China
81. Actavis S.à.r.l.	Luxembourg
82. Paomar Plc.	Cyprus
83. "Specifar"	Greece
84. Alet	Greece
85. Actavis Pharma Pty Ltd	Australia
86. Ascent Pharmahealth Pty Ltd	Australia
87. Actavis Australia Pty Ltd	Australia
88. Ascent Australia Pty Ltd	Australia
89. Actavis Pty Ltd	Australia
90. Ascent Pharma Pty Ltd.	Australia

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
91. Ascent Pharmahealth Asia Pte Ltd	Singapore
92. Drug Houses of Australia Pte Ltd.	Singapore
93. Ascent Pharmahealth Hong Kong Ltd.	Hong Kong
94. Actavis Sdn. Bhd.	Malaysia
95. Arrow Group ApS	Denmark
96. Arrow ApS	Denmark
97. Makewhey Products Pty. Ltd.	South Africa
98. Actavis Holdings South Africa (Pty) Ltd.	South Africa
99. Actavis Pharma (Pty) Ltd.	South Africa
100. Actavis (Pty) Ltd.	South Africa
101. Scriptpharm Marketing (Pty) Ltd	South Africa
102. Referral-Net (Pty) Ltd.	South Africa
103. Spear Pharmaceuticals (Pty) Ltd	South Africa
104. Pharmascript Pharmaceuticals Ltd.	South Africa
105. Arrow Pharma Tender (Pty) Ltd.	South Africa
106. Scriptpharm Risk Management (Pty) Ltd.	South Africa
107. Imbani Pharmaceuticals (Pty) Ltd.	South Africa
108. Zelphy 1308 (Pty) Ltd.	South Africa
109. Arrow Poland SA	Poland
110. Arrowblue Produtos Farmaceuticos SA	Portugal
111. Bowmed Ltd	UK
112. Selamine Ltd.	Ireland
113. Arrow Blue Ltd	Israel

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
114. Seeker Investments Ltd.	BVI
115. SC Pharma (Pty) Ltd.	Australia
116. Spirit Pharmaceuticals NZ Pty Ltd.	New Zealand
117. Willow Pharmaceuticals Pty Ltd.	Australia
118. Medis Pharma Pty Ltd	Australia
119. Eremad Pty Ltd.	Australia
120. Arrow Läkemedel AB	Sweden
121. Arrow Generics Ltd.	UK
122. Arrow No 7 Ltd	UK
123. Breath Ltd	UK
124. Soosysoo Ltd.	BVI
125. Actavis New Zealand Limited	New Zealand
126. Watson Laboratories, S. de R.L. de C.V	Mexico
127. Actavis Canada Company	Canada
128. Actavis Pharma Company	Canada
129. 3242038 Nova Scotia Company	Canada
130. Abri Pharmceuticals Company	Canada
131. Actavis Pharma Holding 4 ehf. (APH4)	Iceland
132. Actavis Pharma Holding 5 ehf. (APH5)	Iceland
133. Actavis Group ehf.	Iceland
134. Actavis Group PTC ehf.	Iceland
135. Actavis Dutch Holding BV	Netherlands
136. LLC Actavis	Russia



<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
137. Actavis Ilacilari AS # TU0000001	Turkey
138. Opening Pharma Bulgaria EOOD	Bulgaria
139. Open Pharma LLC	Russia
140. Actavis ehf.	Iceland
141. Medis ehf.	Iceland
142. Medis Pharma France SAS	France
143. Medis-Danmark A/S. # DA000003	Denmark
144. Actavis Ireland Ltd.	Ireland
145. Actavis Italy S.p.A. # IT000001	Italy
146. Actavis Isle of Man Ltd.	Isle of Man
147. Actavis Nordic A/S # DA000002	Denmark
148. Actavis Oy	Finland
149. UAB Actavis Baltic	Lithuania
150. Actavis Holding AB	Sweden
151. Actavis AB	Sweden
152. Actavis Holding Germany GmbH	-
153. Medis Pharma GmbH	Germany
154. Actavis A/S #DA000001	Denmark
155. Actavis Norway AS	Norway
156. Actavis, S. de. R.L. de C.V.	Mexico
157. Actavis Pharma S. de R.L. de C.V.	Mexico
158. Actavis Hungary Kft.	Hungary
159. Arrow Pharm (Malta) Ltd.	Malta

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
160. Medis Pharma BV	Netherlands
161. PharmaPack International B.V.	Netherlands
162. Actavis Polska Sp. z.o.o.	Poland
163. Actavis International Ltd.	Malta
164. Actavis Malta Ltd.	Malta
165. Actavis Export International Ltd.	Malta
166. Actavis Ltd.	Malta
167. Actavis GmbH	Austria
168. Actavis Holdings UK Ltd.	UK
169. Actavis Holdings UK II Ltd.	UK
170. Actavis UK Ltd.	UK
171. Warner Chilcott Acquisition Limited	UK
172. Chilcott UK Limited	UK
173. Warner Chilcott Research Laboratories Ltd.	UK
174. Warner Chilcott UK Limited	UK
175. Warner Chilcott Pharmaceuticals UK Limited	UK
176. Warner Chilcott Deutschland GmbH	Germany
177. Millbrook (NI) Limited	UK
178. Auden Mckenzie Holdings Ltd.	UK
179. Auden Mckenzie (Pharma Division) Ltd.	UK
180. NRIM Ltd.	UK
181. Lime Pharma Ltd.	UK
182. D3 Pharma Ltd.	UK



<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
183. Actavis d.o.o. Belgrade	Serbia
184. Lotus Laboratories Private Ltd.	India
185. Actavis Ukraine LLC	Ukraine
186. Zdravlje AD	Serbia
187. Actavis Switzerland AG	Switzerland
188. Oncopharma AG # SZ000001	Switzerland
189. Sindan Pharma SRL	Romania
190. Actavis SRL	Romania
191. Sindan Foundation	Romania
192. Actavis CZ a.s. # EZ000001	Czech Republic
193. Actavis S.r.o.	Slovak Republic
194. Biovena Pharma Sp. z.o.o.	Poland
195. Actavis (Cyprus) Ltd.	Cyprus
196. Actavis Operations EOOD	Bulgaria
197. Balkanpharma Troyan AD	Bulgaria
198. Balkanpharma Dupnitsa AD	Bulgaria
199. Balkanpharma Security EOOD	Bulgaria
200. Balkanpharma Healthcare International (Cyprus) Ltd.	Cyprus
201. Actavis EAD	Bulgaria
202. Actavis Istanbul Ilac Sanayive Ticaret Ltd. Sirketi	Turkey
203. Actavis (MEEA) FZE	UAE
204. Actavis Farmacêutica Limitada	Brazil
205. Actavis Holding Asia BV	Netherlands

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
206. Actavis Hong Kong Limited	Hong Kong
207. China Medical & Chemical Industrial Development Group Ltd.	China
208. Actavis Pharma Development Centre Private Ltd.	India
209. Actavis Pharma Private Ltd.	India
210. PT Actavis Indonesia	Indonesia
211. Actavis ASKA KK	Japan
212. Actavis KK # JA0000001	Japan
213. Actavis (Asia Pacific) Pte. Ltd.	Singapore
214. Actavis Thailand Co., Ltd. (f/k/a Silom Medical Co., Ltd)	Thailand
215. Silom Medical International Co., Ltd.	Thailand
216. Forest Laboratories UK Ltd.	UK
217. Pharmax Ltd.	UK
218. Forest Pharma BV	Netherlands
219. Forest Laboratories Osterreich GmbH	Austria
220. Forest Laboratories Denmark ApS	Denmark
221. Forest Laboratories France S.A.S.	France
222. Forest Laboratories Deutschland GmbH	Germany
223. Forest Laboratories Italy S.r.L.	Italy
224. Forest Laboratories Spain, SL	Spain
225. Forest Laboratories Switzerland GmbH	-
226. Axcan France (Invest) SAS	France
227. Actavis Biopharma SAS	France
228. Aptalis Pharma SAS	France

<i>Company Name</i>	<i>Jurisdiction of Incorporation</i>
229. Forest Tosara Ltd.	Ireland
230. Allergan UK LLP	UK
231. Actavis Laboratories UT, Inc.	Delaware
232. Watson Laboratories, Inc.	Nevada
233. Actavis Pharma, Inc.	Delaware
234. Arrow International Ltd.	Malta
235. Allergan UK Group Ltd.	UK

**Schedule 4.8(j)**

In the event that the Transactions constitute the transfer by Seller Parent of assets with a total gross fair market value exceeding one third of all of the assets of Seller Parent (as determined under Section 1.280G-1 (Q/A 6)), certain payments or benefits to the Business Employees who are "disqualified individuals" (as determined under Section 1.280G-1 (Q/A 15-21)) could constitute "excess parachute payments" for purposes of Section 280G of the Code.

In the event that the Transactions constitute the sale by Seller Parent of assets exceeding fifty percent (50%) of all of the assets of Seller Parent, the Transactions could trigger enhanced severance, vesting or other benefits for the Business Employees under certain of the Seller Benefit Plans or the Transferred Entity Benefit Plans.

Provided that the foregoing thresholds are not exceeded, no change in control benefits or payments should be payable to the Business Employees as a result of the Transactions.

#### **Schedule 4.10(a) – Business Contracts**

- Development and Commercialization Agreement, dated March 27, 2009, by and among 3M Company, 3M Innovative Properties Company and Actavis Inc. (as amended on July 20, 2010, January 11, 2011, March 14, 2011, September 11, 2012 and September 19, 2014).
- Share and Asset Purchase Agreement, dated March 28, 2014, by and among Actavis Holding NWE B.V., Actavis Holding B.V., Actavis Holding Germany GmbH, Arrow Group ApS, Actavis A/S, Actavis Italy SpA, Actavis, Inc., as Vendor Guarantor, Agile Pharma B.V., as Purchaser, and Helix Healthcare B.V., as Purchaser Guarantor.
- License and Supply Agreement, dated April 1, 2014, between Medis eff. and Agile Pharma B.V.
- Distribution Agreement, dated April 1, 2014, between Actavis Group PTC ehf and Agile Pharma B.V.
- License and Distribution Agreement, dated April 1, 2014, between Medis ehf and Agile Pharma B.V.
- Supply Agreement, dated June 10, 2010 between The RiteDose Corporation and Watson Laboratories, Inc. (as amended on June 1, 2012 and August, 2012).
- Manufacturing Services Agreement, dated February 20, 2004, between Patheon Inc. and Watson Laboratories, Inc. (as amended on January 1, 2008, February 1, 2012 and May 15, 2013).
- Development, Supply and License Agreement, dated December 21, 2009, between Watson Pharmaceuticals, Inc. and Indoco Remedies Ltd. (as amended March 24, 2011).
- Amended and Restated Supply Agreement, dated December 19, 2014, by and among Actavis Pharma Inc., Actavis Mid Atlantic LLC and G&W Laboratories, Inc.
- Supply Agreement, dated October 23, 2009, between Breath Ltd. and Catalent Pharma Solutions, LLC.
- Sale and Purchase Agreement for the Share Capital of Silom Medical Company Limited and Silom Medical International Company Limited, dated March 31, 2014, among ASEAN Pharma Holding Limited, Ms. Preeya Sibunruang and others, and Actavis Holding Asia B.V.
- Sale and Purchase Agreement for Shares in Silom Medical Company Limited and Silom Medical International Company Limited, dated March 31, 2014, between Thai Individual Shareholders and Actavis Holding Asia B.V.

- Joint Venture Agreement, dated March 6, 2009, between Actavis Holding Asia B.V. and ASKA Pharmaceutical Co., Ltd.
- Actonel Promotion and Distribution Agreement, dated as of January 15, 2015 by and between Warner Chilcott Company, LLC and Sanofi Winthrop Industrie.
- Transition Agreement, dated as of October 31, 2014, between Warner Chilcott Company, LLC and Sanofi-Aventis U.S. LLC.
- Actonel Promotion and Distribution Agreement, dated as of January 30, 2014, by and between Warner Chilcott Company, LLC and Sanofi Winthrop Industrie.
- Seller Parent has over 100 licensing agreements for supply of products in specific markets or territories, which were entered into in the Ordinary Course of Business. These agreements are consistent with the standards in the industry. They typically are for a term of 3-5yrs, with the option to extend. Pricing varies by contract, but typically include a sales royalty and/or a floor price for product supply. These contracts contain exclusivity provisions granted by the Business, which are not individually material to the Business.
- Settlement Agreement, dated March 23, 2013, between Watson Laboratories, Inc., EGIS Pharmaceuticals PLC, AstraZeneca AB and Shionogi Sieyaku Kabushiki Kaisha in connection with approvals requested from the FDA for a rosuvastatin zinc product (NDA No. 202-172) and a rosuvastatin calcium product (ANDA No. 79-167).

Transferred Leased Real Property

Country	City, State	Dataroom Reference	Address	Area square footage	OWNED / LEASED	Lease Expiry or 1st Break	Base Rent
United States	Parsippany NJ	8.7.6.46.8.5	400 Interpace Parkway	224,294	LEASED	31-Dec-22	\$6,845,744
United States	Weston FL	8.7.6.46.4.4.2	2945 West Corporate Lakes Boulevard	128,840	LEASED	14-Oct-19	\$1,497,228
United States	Morristown, NJ	8.7.6.46.8.3	60 Columbia Rd. Building B	51,729	LEASED	29-Feb-20	\$1,293,225
Iceland	Hafnarfjordur	8.7.6.18.1.4	Dalshraun 1	30,591	LEASED	31-Aug-20	\$1,280,526



**Schedule 4.10(b) – Seller Material Contracts**

- Actavis, Inc. has been in correspondence with Agile Pharma BV relating to a potential claim relating to rebates under an indemnity for tender penalties relating to an AOK tender for Pantoprazole contained in transaction documents relating to the sale of its Western European generics business on 1 April 2014. No request for indemnification has yet been received. Actavis, Inc. is still assessing the merits of any potential indemnity claim with its counsel, but in any event it considers its liability under the indemnity to be capped at a maximum of €5,000,000 pursuant to the licence and supply agreement entered into between Medis and Agile Pharma BV.

**Schedule 4.10(c) – Renegotiation of Seller Material Contracts**

The Business is currently renegotiating its contracts with Catalent Pharma Solutions, LLC and a new agreement is expected to be entered into shortly following signing of this Agreement.

**Schedule 4.11 – Investigations; Litigation.**

Generic Opana ER patent infringement litigations (Endo Pharms. Inc. et al. v. Actavis Inc. et al., Case Nos. 12-cv-8985-Griesa (S.D.N.Y.); 14-cv-01381 – Andrews (D. Del.))

Generic Lysteda patent infringement litigation (Ferring B.V. v. Actavis, Inc. et al. 2:15-cv-04222-KSH-CLW (D.N.J.))

Generic Opana ER false advertising litigation (Endo Pharms. Inc. v. Actavis, Inc., Case No. 2:12-cv-07591-KM-SCM (D.N.J.))

Generic Valsartan patent proceedings in Finland.

Generic Aripiprazole patent proceedings in Turkey.

The litigation shown in the excel file entitled “TRUMP-Commercial Litigation Log.xlsx” to the extent Related to the Business, the final version of which was emailed to Jinhee Chung at Sullivan & Cromwell by Andrew Clark of Latham & Watkins at 03.04 AM on July 27, 2015.

On June 26, 2015, Allergan, Inc. received a grand jury subpoena from the United States Department of Justice, Antitrust Division. The subpoena seeks information for the period from January 1, 2012 through the present. The Antitrust Division is seeking information relating primarily to three generic products: Butalbital, Doxycycline and Probenecid. The subpoena requests information relating to the pricing of each of these drugs as well as any communications with competitors or other third parties relating to these products. In addition, the subpoena seeks information relating to corporate and employee organizational structures and company policies and procedures.

IRS investigation relating to treatment of legal costs relating to patent infringement cases (further detail provided in Schedule 4.14).

**Schedule 4.12(a) – Regulatory Permits**

None.

**Schedule 4.12(b) – Compliance with Health Care Laws**

- ACT Poland will be unable to comply with the new Good Distribution Practice (“GDP”) requirements coming into effect in Poland on April 1, 2016. To address this issue, ACT Poland will develop an interim solution to be implemented after signing, which solution will not have a material adverse effect on the Business.

**Schedule 4.12(d) - Recalls**

- Recall of Lutera ® 0.1mg-0.02mg (Levonorgestrel – Ethinyl Estradiol) on June 4, 2015 due to product lots packaged with outdated inserts; FDA letter received June 30, 2015; recall ID D-1148-2015, classification III.
- Recall of Rosuvastatin 5mg F/C tablets on February 26, 2015 due to 5-ketoacid impurity failure in product distributed in Australia, Slovenia, Ukraine, Moldova, Russia, Uzbekistan, Kazakhstan, Hong Kong and Malta; recall classification TBD.
- Recall of Vancomycin HCL 125MG CAP 2 X 10 NDC 0591-3560-15 and Vancomycin HCL 250MG CAP 2 X 10 NDC 0591-3561-15 on February 12, 2015 due to potency testing results below USP specifications; FDA letter received March 30, 2015, recall classification II.

**Schedule 4.14 – Tax Matters**

Tax items under exam for which the Company has concluded a tax reserve is not required under U.S. GAAP include but is not limited to the following:

Issue	Description
a. Deductibility of AWP settlement payments (US federal and state)	Several of the Company's subsidiaries settled various claims under the False Claims Act (for both federal and state purposes) related to whether allegedly improper price reporting by pharmaceutical manufacturers led to increased payments by various government agencies. The Company deducted the related settlement payments as ordinary and necessary business expenses pursuant to Code Section 162. The Internal Revenue Service ("IRS") has argued that some or all of these expenses are non-deductible fines or penalties pursuant to Code Section 162(f). This issue exists for all open years, some of which are currently under examination.
b. Patent infringement litigation costs (US federal and state)	In the ordinary course of its business, the Company incurred legal costs to defend itself against patent infringement lawsuits. The Company deducted these legal costs as ordinary and necessary business expenses pursuant to Code Section 162. The IRS has argued that some or all of these legal costs should be capitalized and amortized as intangible assets. This issue exists for all open years, some of which are currently under examination.
c. Intercompany Financing (US federal and state)	The Company's US subsidiaries deducted interest expense related to notes due to certain non-US affiliates. The Company concluded that these notes were debt for US tax purposes any related interest expense was deductible. Furthermore, the Company concluded that no limitations were applicable to limit the interest deduction under Code Section 163(j) or any other provisions of the Code. Further, the Company concluded that no withholding tax was due when the interest payments were made to the non-US affiliates. The Company has not recorded any income tax reserves related to the intercompany financing transactions.
d. Intercompany Financing (Iceland):	Certain Icelandic subsidiaries deducted interest expense related to notes due to non-US affiliates. The Company concluded that this interest was fully deductible. The Company has not recorded any income tax reserves related to the Icelandic intercompany financing transactions.
e. Intercompany Financing (UK):	Certain UK subsidiaries deducted interest expense related to notes due to certain non-US affiliates. The Company concluded that these notes were debt for UK tax purposes and the related interest was fully deductible. Furthermore, the Company concluded that no limitations were applicable



	under any other provisions of the UK tax law. The Company has not recorded any income tax reserves related to this intercompany financing transaction.
f. Unremitted Earnings of affiliates	No liability or reserve has been provided for the tax cost of repatriating earnings of subsidiaries. The Company intended that these amounts were indefinitely reinvested.
g. Interest income of Iceland PTC (US federal and state)	Iceland PTC holds receivables and receives interest income from certain US entities. For periods when Iceland PTC was a controlled foreign corporation ("CFC"), no portion of Iceland PTC's income was included in US taxable income as the CFC had no positive accumulated or current earnings and profits. No income tax reserve has been provided.
h. Deemed Liquidation of Actavis, Inc. SCS (US federal and state)	No reserve has been provided related to either the fair value or tax basis of the interests in Actavis, Inc. SCS at the time of its deemed liquidation for US tax purposes in 2012, which was a reportable loss transaction under the Code.
i. Legal entity reorganization (Russia)	Prior to April 2010, Actavis OOO (Russia) was owned 90% by Balkanpharma OOO (Bulgaria). At the time, Balkanpharma OOO was a dormant company that was owned by Actavis EAD, a Bulgarian entity. The Company restructured this ownership by merging Balkanpharma into Actavis OOO, which resulted in one shareholder in Actavis OOO, which was a Dutch holding company. This item has not been examined by the relevant taxing authorities.
j. Withholding tax (Russia)	Withholding tax may apply to interest payments between Actavis PTC ehf. and Actavis OOO, depending on the nature of the underlying loan in the eyes of relevant taxing authorities. No reserve has been recorded for this item.
k. Transaction costs (US federal and state)	The company deducted certain costs incurred in connection with acquisitions of assets and shares. The Company has not recorded a tax reserve for this item.
l. State nexus (Various US state and local)	Certain states have or could argue that the Company has nexus and should file income tax returns in their jurisdictions. The Company has not recorded a tax reserve for all jurisdictions.
m. Permanent Establishment Risk (Italy)	The Company received a notice for non-filing of a tax return in Italy related to the Medis business. The Company believes it is more likely than not that activities rose to the level of a permanent establishment, and has recorded a reserve in connection with the non-filing notice accordingly.
n. Intercompany financing (France)	Axcan France claimed tax deductions related to interest expense arising from loans with an entity based in a low tax jurisdiction

o. Foreign Exchange Loss (US federal and state)	The Company deducted a foreign exchange loss related to the refinancing of certain intercompany payables for US federal and state tax purposes. The Company has not recorded a tax reserve for this item.
p. Withholding tax (US federal and state)	The Company makes various payments to related and unrelated non-US persons. The IRS may question the sufficiency of documentation supporting the need to withhold on these payments. The Company has not recorded a tax reserve for this item.

The following is a list of tax items under exam for which the Company has concluded a tax reserve is required under U.S. GAAP:

Issue	Description
a. Section 199 deduction in short taxable years (US federal and state)	The Company has provided a full tax reserve for its 199 deductions generated in short taxable years related to potential wage limitations.
b. Section 199 deduction, all other (US federal and state)	The Company has provided a reserve for a portion of the domestic manufacturing deduction taken on its US federal tax returns due to possible IRS challenges to deduction calculations.
c. Research and Development credit (US federal and state)	The Company has provided a reserve for a portion the research and development credit taken on its US federal tax returns to reflect possible IRS challenges to credit calculations.
d. Non-US charge out of a management fee from Actavis PTC to other affiliates (Various non-US jurisdictions)	The Company has provided a partial tax reserve for tax deductions taken by affiliates of PTC for management charges from PTC.
e. Non-US Charge back of severance expenses to Warner Chilcott Company, LLC (Germany, UK and Puerto Rico)	The Company accrued severance payments in the U.K., Puerto Rico and Germany. The severance expenses in the U.K. and Germany were included as part of the transfer pricing adjustments and, as result, were borne by Warner Chilcott Company, LLC. Therefore, the tax exposure with respect to this item is in Puerto Rico. Income tax reserves were established for the U.K. and German severance expenses borne by Puerto Rico as the tax authorities could argue that Puerto Rico has no contractual obligation to bear the economic cost of these expenses.
f. Asset sale (Spain)	In 2004, Actavis Pharma Iberia S.L. sold assets to the Vita Group. The sale generated a loss for tax purposes. This loss could be challenged by the Spanish tax authorities when the Net Operating Losses are utilized. An income tax reserve

	has been established for this item.
g. Charitable Contributions (US federal and state)	The Company claimed a deduction for donated inventory at twice cost. The IRS challenged both Actavis' fair market value of the donated drugs and the impact of expiration dates. The IRS has argued that these deductions were overstated. Moreover, the IRS contended that donated products with near term expiration dates should be valued at zero and therefore no charitable deduction should be allowed.
h. Combined filing (US state, Indiana)	Actavis Pharma, Inc. filed its Indiana Corporate Income tax return on a separate state filing basis. The Company has recorded a reserve related to the risk that its intercompany transactions with Actavis, Inc. and Subsidiaries could be included in the Indiana filing.
i. Net operating loss (US state, Florida)	On its Florida income tax returns, the Company claimed certain net operating losses and other deductions which may not have been available for use due to certain subsidiaries not having filed pre-consolidated separate tax returns.
j. Actavis Pharma net operating loss (Various US state)	Actavis, Inc. has recorded an income tax reserve related to certain net operating loss carryovers generated in the Actavis Pharma, Inc. separate states. The net operating losses were generated primarily from interest expenses arising from debt used to acquire Schein Pharmaceutical, Inc. There is uncertainty whether the separate states would allow the interest expenses that resulted in the creation of the net operating losses.
k. Intercompany transactions (US state, Wisconsin)	The company has recorded reserves related to the arm's length pricing of certain intercompany transactions.
l. Location Savings (India)	During the audit for the assessment year 2008-2009, Watson Pharma Private Limited was assessed with additional tax liabilities related to "location savings" associated with the contract manufacturing and research and development service segments that it operated. The "location savings" argument attributes additional income to an Indian entity resulting from a comparison of the cost of operating a branch in India compared to operating a branch in other, arguably, more expensive locations.
m. Transfer Pricing (Italy)	The amount of profit earned by Actavis Italy SpA was less than the 3% markup that is generally earned pursuant to the Actavis group transfer pricing policy. Due to the significant Italian cost structure and higher costs of buying third party products, the PTC would have had to compensate Actavis Italy SpA for an amount that would have been higher than its costs of goods sold.

n. Transfer Pricing – certain Warner Chilcott Distributors (Various non-US)	Warner Chilcott operates limited-risk distributors (“LRDs”) in the United Kingdom (“WCUK”), France (“WC France”), Spain (“WC Spain”), Italy (“WC Italy”) and Germany (“WC Germany”). WC restructured a number of its European operations effective with the start of the fourth quarter of FY 2011. The level of remuneration for several of Warner Chilcott’s European distributors was reduced to reflect an appropriate arm’s length level of compensation consistent with the reduction in the scope of functions performed by these entities following the restructuring.
o. Sale of assets (Bulgaria)	A tax loss resulting from the sale of Balkanpharma Razgrad may be challenged by the tax authorities.
p. Intercompany financing and asset sales (Denmark)	The Actavis Danish entities are Actavis Nordic A/S, Actavis A/S, Colotech A/S, and Medis-Danmark A/S (in Liquidation) which file a consolidated tax return in Denmark. The Company had taken tax deductions related to interest expense, amortization related to Alpharma offset by a small gain on the sale of Alpharma. The Company has recorded a tax reserve for these deductions.
q. Transfer Pricing (Canada)	Actavis Canada Company and/or its predecessors entered into certain intercompany transactions with related parties. These transactions include contract R&D services, royalty payments for the use of proprietary formulations, and cost reimbursement transactions. In addition, the Company took SR&D benefits related to research and development activities of the Company. The Company has recorded a tax reserve for these intercompany transactions.

The following is a list of ongoing US federal audits:

- a) U.S. federal income tax audit, currently in appeals, for the tax years ended 12/31/2008 and 12/31/2009 for Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.).
- b) U.S. federal income tax audit for the tax years ended 12/31/2010 and 12/31/2011 for Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.).
- c) U.S. federal income tax audit for the tax years ended 12/31/2009, 12/31/2010, 12/31/2011 and 10/31/2012 for Actavis LLC (f/k/a Actavis Inc.).

The following is a list of ongoing non-US audits:

Legal Entity	Country	Years
Balkanpharma Troyan AD	Bulgaria	2008-2010
Cobalt Pharma Inc.	Canada	2011-2012
Actavis A/S, Actavis Nordic A/S, Colotech A/S	Denmark	2007-2011
Arrow Pharma ApS	Denmark	2009-2014

Arrow Group ApS	Denmark	2011
Actavis OY	Finland	2013 - 2014
Aptalis Pharma SAS	France	10/1/2009 - 09/30/2012
Medis ehf	Italy (Iceland)	2011-2012
Actavis ehf	Italy	All Years
Actavis Group ehf	Iceland	All Open Years
Lotus Laboratories Pvt Ltd	India	2010-2012
Watson Pharma Pvt Ltd	India	2008-2012
Actavis Pharma Development Center Pvt	India	2011-2012
Warner Chilcott Ltd	Ireland	2012
Actavis Italy S.P.A.	Italy	2011-2013
Actavis New Zealand Ltd	New Zealand	2012-2014
Biovena Pharma Sp.	Poland	2010-2011
Actavis Polska sp. Z.o.o.	Poland	All Open Years
Actavis OOO	Russia	All Open Years
Zdravlje doo	Serbia	2013
Zdravlje doo	Serbia	December 2014
Actavis Switzerland AG	Switzerland	2011-2012
Forest Laboratories UK Ltd.	UK	All Open Years

The following is a list of ongoing U.S. state audits:

Legal Entity	State	Years
Actavis Inc.	New York	2011
WPI & Subs	California	2000 – 2004 & 2007
Watson Pharma and Affiliates	Georgia	2000 - 2008
WPI & Subs	Illinois	2000 – 2003
WPI & Subs	Massachusetts	2011 – 2012
Watson Pharma and Affiliates	Michigan	2008 – 2011
Watson Pharma and Affiliates	Minnesota	2009 – 2011
WPI & Subs	New York State	2006 – 2008
WPI & Subs	New York State	2009 – 2011

US federal statute waivers:

Federal - IRS Audit			
Actavis, Inc. (fka: Watson Pharmaceuticals, Inc. &	12/31/2008 and	6/30/2016	



Subs)	12/31/2009		
Actavis, Inc. (fka: Watson Pharmaceuticals, Inc. & Subs)	12/31/2010 & 12/31/2011	12/31/2016	Income Tax
Cobalt Laboratories, Inc.	12/31/2010	6/30/2015	Withholding Tax
Watson Laboratories, Inc.	12/31/2010	6/30/2015	Withholding Tax
Actavis Inc. (Legacy)	12/31/2009-12/31/2012	11/30/2016	Income Tax

US state and local statute waivers:

Legal Entity	State	Years	Waiver Extending SOL
WPI & Subs	Illinois	2000 to 2003	<b>December 31, 2015</b>
WPI & Subs	Massachusetts	2011 to 2012	<b>April 30, 2016</b>
WPI & Subs	New York	2006 to 2008	<b>September 30, 2015</b>
WPI & Subs	New York	2009 to 2011	<b>December 31, 2015</b>

Actavis, Inc. has certain indemnification obligations under Share and Asset Purchase Agreement, dated March 28, 2014, by and among Actavis Holding NWE B.V., Actavis Holding B.V., Actavis Holding Germany GmbH, Arrow Group ApS, Actavis A/S, Actavis Italy SpA, Actavis, Inc., as Vendor Guarantor, Agile Pharma B.V., as Purchaser, and Helix Healthcare B.V., as Purchaser Guarantor.

Aptalis Pharma SAS has certain indemnification obligations under the Stock and Asset Purchase Agreement dated February 12, 2015 by and between Aptalis Holdings Inc. and TPG Indigo S.à.r.l.

Actavis, Inc. and the other US entities in the Transferred Group are members of a US consolidated federal income tax group which includes certain Sellers and Seller Affiliates.

In 2009, Watson Pharmaceuticals, Inc. and Subsidiaries ("Watson") retired the \$575 million face amount of the Debt for its face amount through a cash payment to holders of the Debt. Watson exercised its optional redemption rights under the terms of the Debt to redeem the Debt for cash. The total consideration paid to retire the Debt was less than the adjusted issue price of the Debt at the time of the conversion. Therefore, Watson should realize Cancellation of Debt ("COD") income of approximately \$214.7 million with respect to the Debt. Under 108(i), Watson elected to defer the recognition of COD income. Instead of recognizing the COD income on Watson's

2009 tax return, the COD income will be ratably included in taxable income over a five-year period from 2014-2018.



**Schedule 4.16(e)– Claims Relating to Intellectual Property**

Generic Opana ER patent infringement litigations (Endo Pharms. Inc. et al. v. Actavis Inc. et al., Case Nos. 12-cv-8985-Griesa (S.D.N.Y.); 14-cv-01381 – Andrews (D. Del.))

Generic Lysteda patent infringement litigation (Ferring B.V. v. Actavis, Inc. et al. 2:15-cv-04222-KSH-CLW (D.N.J.))

Generic Opana ER false advertising litigation (Endo Pharms. Inc. v. Actavis, Inc, Case No. 2:12-cv-07591-KM-SCM (D.N.J.))

Generic Valsartan patent proceedings in Finland.

Generic Aripiprazole patent proceedings in Turkey.

The Seller Parent and its Subsidiaries have been involved in the following “at risk” launches:

1. Opana ER (Endo Pharms. Inc. et al. v. Actavis Inc. et al., Case Nos. 12-cv-8985-Griesa (S.D.N.Y.); 14-cv-01381 – Andrews (D. Del.))
2. Lysteda (Ferring B.V. v. Actavis, Inc. et al. 2:15-cv-04222-KSH-CLW (D.N.J.))
3. Lovenox (U.S.)
4. Aripiprazole (Turkey)
5. Pregabalin (Warner-Lambert Company LLC v Actavis Group PTC ehf, Actavis UK Limited, Caduceus Pharma Limited - re Pregabalin, Claim No. HC-2014-001795)
6. Escitalopram (Denmark) (H Lundbeck A/S v Actavis A/S re Escitalopram, case number T-0010-11)
7. Valsartan (Finland) (Actavis Oy v Novartis AG, re Valsartan, case number S 12/1879)
8. Rosuvastatin (Australia) (Watson Pharma Pty Ltd v AstraZeneca AB, AstraZeneca AB v Ascent Pharma Pty Ltd NSD208/2012 and NSD2342/2011 re Rosuvastatin)
9. Quetiapine (Switzerland) (Actavis Switzerland AG v AstraZeneca AB, re Quetiapine SR).
10. Entacapone Triple Combination (multiple markets) (Actavis Group PTC ehf v Orion Corporation in the UK High Court HP14 A 01644 re Entacapone triple combination)

11. Rivastigmine Patch (Novartis AG and others v Focus Pharmaceuticals and Actavis UK Limited, in the UK High Court HP13 D 03312 re Rivastigmine patch)

**Schedule 4.16(k) – Paragraph IV Products**

The following chart lists those products for which Actavis believes it has either exclusive or shared first-to-file status.

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Acetaminophen/Oxycodone ER Tablets</b> (Xartemis XR), Mallinckrodt/Depomed 325/7.5mg	<b>Exclusive</b>
<b>Adapalene/Benzoyl Peroxide Topical Gel</b> (Epiduo), Galderma/Nestle 0.1%/2.5%, tube	<b>Exclusive</b>
<b>Ambrisentan Tablets</b> (Letairis), Gilead 5mg, 10mg	<b>Exclusive</b>
<b>Ascorbic Acid/PEG 3350/Potassium Chloride/Sodium Ascorbate/Sodium Chloride/Sodium Sulfate Powder for Solution</b> (Moviprep), Valeant 4.7/100/1.015/5.9/2.691/7.5g	<b>Exclusive</b>
<b>Benzoyl Peroxide/Clindamycin Topical Gel</b> (Acanya), Valeant 2.5%/1.2%, pre-mixed pump	<b>Exclusive</b>
<b>Brimonidine tartrate Topical Gel</b> (Mirvaso), Galderma/Nestle 0.33%	<b>Exclusive</b>
<b>Budesonide ER Tablets</b> (Uceris), Cosmo/Valeant 9mg	<b>Exclusive</b>
<b>Buprenorphine Patch</b> (Butrans), Purdue 5mcg, 10mcg, 20mcg (FTF confirmed, 3M ANDA) 15mcg (FTF confirmed, SLC ANDA)	<b>Exclusive</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Buprenorphine/Naloxone ODT</b> (Zubsolv), Orexo 1.4/0.36mg, 5.7/1.4mg	<b>Exclusive</b>
<b>Buprenorphine/Naloxone Thin Film</b> (Suboxone), Indivior 2/0.5mg, 8/2mg, 4/1mg, 12/3mg	<b>Exclusive</b>
<b>Bupropion SR/Naltrexone ER Tablets</b> (Contrave), Orexigen/Takeda 90/8mg	<b>Exclusive</b>
<b>Clindamycin Vaginal Cream</b> (Clindesse), Perrigo 2%	<b>Exclusive</b>
<b>Clindamycin Phosphate/Tretinoin Topical Gel</b> (Ziana), Valeant 1.2%/0.025%	<b>Exclusive</b>
<b>Deferasirox Dispersible Tablets for Suspension</b> (Exjade), Novartis 125mg, 250mg, 500mg	<b>Exclusive</b>
<b>Diclofenac Potassium Soft Gel Capsules</b> (Zipsor), Depomed 25mg	<b>Exclusive</b>
<b>Diclofenac Sodium Topical Solution</b> (Pennsaid 2%), Horizon 2%	<b>Exclusive</b>
<b>Dienogest/Estradiol Valerate Tablets</b> (Natazia), Bayer 3mg EV 2/3mg EV/Dienogest 1mg EV 2/2mg EV/D	<b>Exclusive</b>
<b>Doxylamine/Pyridoxine ER Tablets</b> (Diclegis), Duchesnay 10/10mg	<b>Exclusive</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Drospirenone/EE plus MTHF Tablets</b> (Beyaz), Bayer 3/0.02mg, 0.451mg	<b>Exclusive</b>
<b>Drospirenone/EE plus MTHF Tablets</b> (Safyral), Bayer 3.0/0.03mg, 0.451mg	<b>Exclusive</b>
<b>Esomeprazole DR Capsules (OTC)</b> (Nexium 24HR), Pfizer/AstraZeneca 20mg	<b>Exclusive</b>
<b>Etonogestrel/EE Vaginal Ring</b> (Nuvaring), Merck/Bayer 0.12mg/0.015mg/24hr	<b>Exclusive</b>
<b>Fentanyl Citrate Sublingual Tablets</b> (Abstral), Galena/Orexo 0.1mg, 0.2mg, 0.3mg, 0.4mg, 0.6mg, 0.8mg	<b>Exclusive</b>
<b>Gabapentin GR Tablets</b> (Gralise), Depomed 300mg, 600mg	<b>Exclusive</b>
<b>Hydrocodone Bitartrate ER Capsules</b> (Zohydro ER), Pernix 10mg, 20mg, 30mg, 40mg, 50mg	<b>Exclusive</b>
<b>Icosapent Ethyl Soft Gel Capsules</b> (Vascepa), Amarin 1g	<b>Exclusive</b>
<b>Imiquimod Topical Cream</b> (Zyclara), Valeant 2.5%	<b>Exclusive</b>
<b>Imiquimod Topical Cream</b> (Zyclara), Valeant 3.75%	<b>Exclusive</b>
<b>Isotretinoin Hard Gel Capsules</b> (Absorica), Cipher/Sun 10mg, 20mg, 30mg, 40mg	<b>Exclusive</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Lenalidomide Capsules</b> (Revlimid), Celgene 5mg, 10mg, 15mg, 25mg	<b>Exclusive</b>
<b>Levalbuterol HFA Aerosol Metered</b> (Xopenex HFA), Sunovion 0.045mg	<b>Exclusive</b>
<b>Methylphenidate ER Powder for Suspension</b> (Quillivant XR), Pfizer 5mg/ml	<b>Exclusive</b>
<b>Methylphenidate Transdermal Patch</b> (Daytrana), Noven 10mg, 15mg, 20mg, 30mg	<b>Exclusive</b>
<b>Morphine ER/Naltrexone Capsules</b> (Embeda), Pfizer 30/1.2mg, 50/2mg, 60/2.4mg, 80/3.2mg, 100/4mg	<b>Exclusive</b>
<b>Niacin/Simvastatin ER Tablets</b> (Simcor), AbbVie 500/40mg	<b>Exclusive</b>
<b>Nicotine Transdermal Patch (OTC)</b> (Nicoderm CQ), GSK 7mg/24hr, 14mg/24hr, 21mg/24hr	<b>Exclusive</b>
<b>Oxcarbazepine ER Tablets</b> (Oxtellar XR), Supernus 150mg, 300mg, 600mg	<b>Exclusive</b>
<b>Oxycodone ER TR Tablets</b> (OxyContin), Purdue Formulation A: 40mg	<b>Exclusive</b>
<b>Oxycodone ER TR Tablets</b> (OxyContin), Purdue Formulation B: 10mg, 15mg, 20mg	<b>Exclusive</b>
<b>Oxymorphone ER TR Tablets</b> (Opana ER), Endo 5mg	<b>Exclusive</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Phentermine/Topiramate ER Capsules</b> (Qsymia), Vivus 3.75/23mg, 7.5/46mg, 11.25/6mg, 15/92mg	<b>Exclusive</b>
<b>Posaconazole DR Tablets</b> (Noxafil), Merck 100mg	<b>Exclusive</b>
<b>Prednisone DR Tablets</b> (Rayos), Horizon 1mg, 2mg, 5mg	<b>Exclusive</b>
<b>Rotigotine Transdermal Patch</b> (Neupro), UCB 1mg, 2mg, 3mg, 4mg, 6mg, 8mg/24hr	<b>Exclusive</b>
<b>Sevelamer Carbonate Powder for Suspension</b> (Renvela), Genzyme/Sanofi 0.8g, 2.4g	<b>Exclusive</b>
<b>Sodium Phosphate Dibasic Anhydrous/Sodium Phosphate Monobasic Monohydrate Tablets</b> (Osmoprep), Valeant 0.398/1.102g	<b>Exclusive</b>
<b>Tacrolimus ER Capsules</b> (Astagraf XL), Astellas 0.5mg, 1mg, 5mg	<b>Exclusive</b>
<b>Tapentadol Oral Solution</b> (Nucynta), Depomed 20mg/ml	<b>Exclusive</b>
<b>Testosterone Topical Solution</b> (Axiron), Lilly 30mg/1.5ml	<b>Exclusive</b>
<b>Testosterone Topical Gel</b> (Fortesta), Endo 2%	<b>Exclusive</b>
<b>Topiramate ER Capsules</b> (Trokendi XR), Supernus	<b>Exclusive</b>



<b>Product Name</b>	<b>Believed First-to-File Status</b>
200mg	
<b>Trazodone Hydrochloride ER Tablets</b> (Oleptro), Endo 150mg, 300mg	<b>Exclusive</b>
<b>Treprostinil Inhalation Solution</b> (Tyvaso), United Therapeutics 1.74mg/2.9ml, ampules	<b>Exclusive</b>
<b>Vardenafil ODT</b> (Staxyn), GSK 10mg	<b>Exclusive</b>
<b>Abiraterone acetate Tablets</b> (Zytiga), Johnson & Johnson 250mg	<b>Shared</b>
<b>Dabigatran Etexilate Capsules</b> (Pradaxa), Boehringer Ingelheim 75mg, 150mg	<b>Shared</b>
<b>Dalfampridine ER Tablets</b> (Ampyra), Elan/Acorda 10mg	<b>Shared</b>
<b>Desvenlafaxine ER Tablets</b> (Pristiq), Pfizer 50mg, 100mg	<b>Shared</b>
<b>Doxepin Hydrochloride Tablets</b> (Silenor), Pernix 3mg, 6mg	<b>Shared</b>
<b>Dronedarone Tablets</b> (Multaq), Sanofi 400mg	<b>Shared</b>
<b>Fesoterodine Fumarate SR Tablets</b> (Toviaz), Pfizer 4mg, 8mg	<b>Shared</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Fingolimod Capsules</b> (Gilenya), Novartis 0.5mg	<b>Shared</b>
<b>Lacosamide Tablets</b> (Vimpat), UCB 50mg, 100mg, 150mg, 200mg	<b>Shared</b>
<b>Lisdexamfetamine Dimesylate Capsules</b> (Vyvanse), Shire/New River 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	<b>Shared</b>
<b>Lurasidone HCl Tablets</b> (Latuda), Sunovion 20mg, 40mg, 60mg, 80mg, 120mg	<b>Shared</b>
<b>Pitavastatin Tablets</b> (Livalo), Kowa 1mg, 2mg, 4mg	<b>Shared</b>
<b>Prasugrel Tablets</b> (Effient), Lilly 5mg, 10mg	<b>Shared</b>
<b>Ramelteon Tablets</b> (Rozerem), Takeda 8mg	<b>Shared</b>
<b>Rasagiline Tablets</b> (Azilect), Teva 0.5mg, 1mg	<b>Shared</b>
<b>Rosuvastatin Tablets</b> (Crestor), AstraZeneca 5mg, 10mg, 20mg, 40mg	<b>Shared</b>
<b>Saxagliptin Tablets</b> (Onglyza), BMS 2.5mg, 5mg	<b>Shared</b>
<b>Sitagliptin Tablets</b> (Januvia), Merck 25mg, 50mg, 100mg	<b>Shared</b>

<b>Product Name</b>	<b>Believed First-to-File Status</b>
<b>Sitagliptin/Metformin Tablets</b> (Janumet), Merck 50/500mg, 50/1000mg	<b>Shared</b>
<b>Tapentadol Tablets</b> (Nucynta), Depomed 50mg, 75mg, 100mg	<b>Shared</b>
<b>Tapentadol ER Tablets</b> (Nucynta ER), Depomed 50mg, 100mg, 150mg, 200mg, 250mg	<b>Shared</b>
<b>Varenicline Tartrate Tablets</b> (Chantix), Pfizer 0.5mg, 1mg	<b>Shared</b>

The following chart lists those products/litigations for which Seller believes it could potentially commence sales without a valid license prior to closing.

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Bortezomib Injection (Velcade®)</b> <i>Millennium Pharmaceuticals v. Actavis Inc.</i> (D. Del. 1:2012-cv-01011-Sleet)	6/8/15
<b>Estradiol Valerate/Dienogest (Natazia®)</b> <i>Bayer v. Watson</i> (D. Del. 1:2012-cv-01726-Stark)	N/A
<b>Levalbuterol Inhalation Aerosol (Xopenex HFA®)</b> <i>Sunovion Pharms. v. Watson</i> (D. Del. 1:2012-cv-00993-Stark)	12/20/14
<b>Oxymorphone Extended-Release Tablets (Opana® ER CRT) “new formulation”</b> <i>Endo v. Actavis, Inc.</i> (S.D.N.Y. 13-cv-0436-Griesa)	6/6/15
<b>Vardenafil ODT (Staxyn®)</b> <i>Bayer v. Watson</i> (D. Del. 1:2012-cv-00517-Sleet)	9/14/14

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Aripiprazole Tablets (Abilify®)</b> <i>Otsuka v. Actavis Inc.</i> (D.N.J. 1:2014-cv-07106-Simandle)	N/A
<b>Lenalidomide Capsules (Revlimid®)</b> <i>Celgene Corp. v. Natco Pharma Ltd.</i> (D.N.J. 10-cv-05197-Wigenton)	4/8/13
<b>Methylphenidate HCl Extended-Release Oral Suspension, CII (Quillivant XR®)</b> <i>Tris Pharma Inc. v. Actavis Laboratories FL Inc.</i> (D. Del. 1:15-cv-00393-Sleet)	N/A
<b>Vardenafil Hydrochloride (Staxyn®)</b> <i>Bayer Pharma AG, et al. v. Watson Laboratories, Inc., et al.</i> (D. Del. 1:12cv-00517-GMS-Sleet)	9/14/14
<b>Drospirenone/EE/Levomefolate and Levomefolate (Beyaz®)</b> <i>Merck &amp; Cie and Bayer v. Watson</i> (D. Del. 1:2013-cv-01272-Andrews)	12/20/15
<b>Ethinyl Estradiol/Etonorgestrel Vaginal Ring (NuvaRing®)</b> <i>Merck v. Warner Chilcott</i> (D. Del. 1:2013-cv-02088-Sleet)	6/24/16
<b>Testosterone Gel, 10 mg/0.5 g (Fortesta®)</b> <i>Endo v. Watson</i> (E.D. Tex. 2:13-cv-00192-Gilstrap)	7/16/15
<b>Bendamustine Injection (Treanda®)</b> <i>Cephalon v. Actavis LLC et al.</i> (D. Del. 1:13-cv-02046-Sleet)	7/2/16

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Buprenorphine/Naloxone Sublingual Film (Suboxone®)</b>  <i>Reckitt Benckiser v. Watson</i> (D. Del. 1:2013-cv-01674-Andrews)	2/28/16
<b>Colchicine Tablets (Colcrys®)</b>  <i>Takeda v. Actavis et al.</i> (D. Del. 1:2014-cv-00268-Robinson)	7/31/16
<b>Doxylamine/Pyridoxine Delayed-Release Tablets (Diclegis®)</b>  <i>Duchesnay Inc. et al. v. Actavis FL</i> (D. Del. 1:2014-cv-00912-McNulty)	12/2/16
<b>Drospirenone/EE/Levomefolate and Levomefolate (Safyral®)</b>  <i>Merck &amp; Cie and Bayer HealthCare Pharms. v. Watson</i> (D. Del. 1:2013-cv-00978-Andrews)	10/24/15
<b>Esomeprazol Delayed-Release Capsules (Nexium®)</b>  <i>AstraZeneca v. Watson</i> (D.N.J. 3:2013-cv-01669-Pisano) – 40 mg	8/4/15
<b>Esomeprazole and Naproxen Delayed-Release Tablets (500/20 mg) (Vimovo®)</b>  <i>AstraZeneca and Horizon v. Watson</i> (D.N.J. 3:2011-cv-02317-Cooper)	9/29/15
<b>Icosapent Ethyl Capsules (Vascepa®)</b>  <i>Amarin v. Watson</i> (D.N.J. 3:2014-cv-03259-Cooper)	10/6/16
<b>Isotretinoin Capsules (Absorica®)</b>  <i>Cipher/Ranbaxy et al. v. Watson Florida et al.</i> (D.N.J. 1:2013-cv-06502-Irenus)	3/16/16

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Lacosamide Tablets (Vimpat®)</b> <i>UCB et al. v. Watson Florida</i> (D. Del. 1:13-cv-01206/1219-Stark)	12/12/15
<b>Oxcarbazepine Extended-Release Tablets (Oxtellar XR®)</b> <i>Supernus v. Watson</i> (D.N.J. 1:2013-cv-04740-Bumb)	12/24/15
<b>Phentermine and Topiramate Extended-Release Capsules (Qsymia®)</b> <i>Vivus v. Watson</i> (D.N.J. 2:2014-cv-03786-Chesler)	11/5/16
<b>Prasugrel Tablets (Effient®)</b> <i>Eli Lilly v. Watson</i> (S.D. Ind. 1:2014-cv-00389-Barker)	7/26/16
<b>Prednisone Delayed-Release Tablets (Rayos®)</b> <i>Horizon v. Watson</i> (D.N.J. 1:2013-cv-05124-Irenus)	1/14/16
<b>Saxagliptin HCl Tablets (Onglyza®)</b> <i>AstraZeneca v. Watson</i> (D. Del. 1:2014-cv-00664-Sleet)	10/19/16
<b>Saxagliptin and Metformin Extended-Release Tablets (Kombiglyze XR®)</b> <i>AstraZeneca v. Watson</i> (D. Del. 1:2014-cv-00664-Sleet)	10/19/16
<b>Sodium Oxybate Oral Solution (Xyrem®)</b> <i>Jazz v. Watson</i> (D.N.J. 2:13-cv-00391-Salas)	6/9/15

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Tapentadol Immediate-Release &amp; Extended-Release Tablets (Nucynta®)</b> <i>Janssen v. Actavis</i> (D.N.J. 2:13-cv-04507-Cecchi)	12/12/15
<b>Tapentadol Oral Solution (Nucynta®)</b> <i>Janssen v. Actavis</i> (D.N.J. 2:14-cv-04617-Cecchi)	12/11/16
<b>Testosterone Topical Solution (Axiron®)</b> <i>Eli Lilly v. Watson</i> (S.D. Ind. 1:2013-cv-00851-Barker)	11/8/15

The following chart lists those products/litigations for which Seller believes the statutory 30-month stays will expire in 2015-16.

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Drospirenone/EE/Levomefolate and Levomefolate (Beyaz®)</b> <i>Merck &amp; Cie and Bayer v. Watson</i> (D. Del. 1:2013-cv-01272-Andrews)	12/20/15
<b>Ethinyl Estradiol/Etonorgestrel Vaginal Ring (NuvaRing®)</b> <i>Merck v. Warner Chilcott</i> (D. Del. 1:2013-cv-02088-Sleet)	6/24/16
<b>Testosterone Gel, 10 mg/0.5 g (Fortesta®)</b> <i>Endo v. Watson</i> (E.D. Tex. 2:13-cv-00192-Gilstrap)	7/16/15
<b>Bendamustine Injection (Treanda®)</b> <i>Cephalon v. Actavis LLC et al.</i> (D. Del. 1:13-cv-02046-Sleet)	7/2/16



<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Buprenorphine/Naloxone Sublingual Film (Suboxone®)</b>  <i>Reckitt Benckiser v. Watson</i> (D. Del. 1:2013-cv-01674-Andrews)	2/28/16
<b>Colchicine Tablets (Colcrys®)</b>  <i>Takeda v. Actavis et al.</i> (D. Del. 1:2014-cv-00268-Robinson)	7/31/16
<b>Doxylamine/Pyridoxine Delayed-Release Tablets (Diclegis®)</b>  <i>Duchesnay Inc. et al. v. Actavis FL</i> (D. Del. 1:2014-cv-00912-McNulty)	12/2/16
<b>Drospirenone/EE/Levomefolate and Levomefolate (Safyral®)</b>  <i>Merck &amp; Cie and Bayer HealthCare Pharms. v. Watson</i> (D. Del. 1:2013-cv-00978-Andrews)	10/24/15
<b>Esomeprazol Delayed-Release Capsules (Nexium®)</b>  <i>AstraZeneca v. Watson</i> (D.N.J. 3:2013-cv-01669-Pisano) – 40 mg	8/4/15
<b>Esomeprazole and Naproxen Delayed-Release Tablets (500/20 mg) (Vimovo®)</b>  <i>AstraZeneca and Horizon v. Watson</i> (D.N.J. 3:2011-cv-02317-Cooper)	9/29/15
<b>Icosapent Ethyl Capsules (Vascepa®)</b>  <i>Amarin v. Watson</i> (D.N.J. 3:2014-cv-03259-Cooper)	10/6/16
<b>Isotretinoin Capsules (Absorica®)</b>  <i>Cipher/Ranbaxy et al. v. Watson Florida et al.</i> (D.N.J. 1:2013-cv-06502-Irenus)	3/16/16

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Lacosamide Tablets (Vimpat®)</b> <i>UCB et al. v. Watson Florida</i> (D. Del. 1:13-cv-01206/1219-Stark)	12/12/15
<b>Oxcarbazepine Extended-Release Tablets (Oxtellar XR®)</b> <i>Supernus v. Watson</i> (D.N.J. 1:2013-cv-04740-Bumb)	12/24/15
<b>Phentermine and Topiramate Extended-Release Capsules (Qsymia®)</b> <i>Vivus v. Watson</i> (D.N.J. 2:2014-cv-03786-Chesler)	11/5/16
<b>Prasugrel Tablets (Effient®)</b> <i>Eli Lilly v. Watson</i> (S.D. Ind. 1:2014-cv-00389-Barker)	7/26/16
<b>Prednisone Delayed-Release Tablets (Rayos®)</b> <i>Horizon v. Watson</i> (D.N.J. 1:2013-cv-05124-Irenus)	1/14/16
<b>Saxagliptin HCl Tablets (Onglyza®)</b> <i>AstraZeneca v. Watson</i> (D. Del. 1:2014-cv-00664-Sleet)	10/19/16
<b>Saxagliptin and Metformin Extended-Release Tablets (Kombiglyze XR®)</b> <i>AstraZeneca v. Watson</i> (D. Del. 1:2014-cv-00664-Sleet)	10/19/16
<b>Sodium Oxybate Oral Solution (Xyrem®)</b> <i>Jazz v. Watson</i> (D.N.J. 2:13-cv-00391-Salas)	6/9/15

<b>Product/Litigation</b>	<b>Believed 30-Month Stay Expiration</b>
<b>Tapentadol Immediate-Release &amp; Extended-Release Tablets (Nucynta®)</b> <i>Janssen v. Actavis</i> (D.N.J. 2:13-cv-04507-Cecchi)	12/12/15
<b>Tapentadol Oral Solution (Nucynta®)</b> <i>Janssen v. Actavis</i> (D.N.J. 2:14-cv-04617-Cecchi)	12/11/16
<b>Testosterone Topical Solution (Axiron®)</b> <i>Eli Lilly v. Watson</i> (S.D. Ind. 1:2013-cv-00851-Barker)	11/8/15

**Schedule 4.17(a) – Transferred Owned Real Property**

Country	City	Address
Brazil	Rio de Janeiro	Rua Barao De Petropolis 293
Brazil	Rio de Janeiro	Rua Barao De Petropolis 311
Bulgaria	Dupnitsa	Samokovsko shosse 3, Buildings 1 through 31
Bulgaria	Sofia	Rainbow Plaze: 29, Atanas Dukov Street, 1407, 2nd and 3rd
Bulgaria	Troyan	1, Krayrechna Str.
Canada	Mississauga	6500 Kitimat Road
China	Shanghai	Suites 3101,3102,3103,3104; 31st Floor Tower B, Eton Plaza ,555 Pudong Dadao
Greece	Athens	Octovriou 28, Agia Varvara
Greece	Schimitari	Thesi Rahili Schimatarion, Oinois 32009
Iceland	Hafnarfjordur	Reykjavikurvegur 76
Iceland	Hafnarfjordur	Reykjavikurvegur 78
Iceland	Hafnarfjordur	Reykjavikurvegur 80
Iceland	Kopavogur	Kársnesbraut 108, 201 Kopavogur
Iceland	Úthlíð, Selfos	Djaknavegur 23 & 27
India	Ambernath	N-15 Additional Ambemath Industrial Area, District 3
India	Ambernath	Plot K -7 Additional Ambemath Industrial Area, District 3
Ireland	Baldoyle	Unit 146, Baldoyle Industrial Estate, Grange Rd
Ireland	Dundalk	Building B, Xerox Technology Park
Italy	Nerviano	Viale Pasteur 10
New Zealand	Auckland	Unit B8, 31-49 Normanby Road, Mt. Eden
New Zealand	Auckland	Unit B9, 31-49 Normanby Road, Mt. Eden
Puerto Rico	Las Crobas	El Conquistador, 1000 Conquistador Ave, Las Croabas, Puerto Rico 00738. Units 5091, 92 and 93
Puerto Rico	Manati	PR Road 2, KM 46.2, Coto Norte Ward
Romania	Bucharest	Bucharest 1, 11 Ion Mihalache blvd.
Romania	Bucharest	Bucharest 1, 179-185 Odai Street
Serbia	Leskovac	Vlajkova 199
Thailand	Phra Nakhon Si Ayutthaya	89 Moo 1, Tambon Ban Chang, Amphoe Uthai

<b>UK</b>	<b>Barnstaple</b>	Barnstaple Site, Whiddon Valley Industrial Estate
<b>UK</b>	<b>Larne</b>	Old Belfast Road, Millbrook
<b>USA</b>	<b>Copiague</b>	200 North Oak Street
<b>USA</b>	<b>Copiague</b>	26 Bethpage Road
<b>USA</b>	<b>Copiague</b>	33 Ralph Ave
<b>USA</b>	<b>Copiague</b>	45 Ralph Ave
<b>USA</b>	<b>Corona</b>	100 Business Center Drive (B2)
<b>USA</b>	<b>Corona</b>	1781 Capital Street
<b>USA</b>	<b>Corona</b>	1791 Capital Street
<b>USA</b>	<b>Corona</b>	311 Bonnie Circle (B4)
<b>USA</b>	<b>Davie</b>	4955 Orange Drive
<b>USA</b>	<b>Elizabeth</b>	200 Elmora Avenue
<b>USA</b>	<b>Grand Island</b>	3000 Alt Blvd
<b>USA</b>	<b>Gurnee</b>	605 Tri-State PKY
<b>USA</b>	<b>Salt Lake City</b>	579 South Chipeta Way

**Schedule 5.2**  
**Share Capital**

Amended and Restated Deposit Agreement, dated November 5, 2012, among Teva  
Pharmaceutical Industries Limited, JPMorgan Chase Bank N.A., as depositary, and the holders  
from time to time of shares

Convertible Senior Debentures issued January 2006 and due in 2026



**Schedule 5.3**  
**Corporate Authority Relative to this Agreement; No Violation**

The following material Contracts contain provisions which may be breached if Closing were to occur without new Debt Financing being put in place by Buyer Parent:

Senior Unsecured Revolving Credit Agreement among Teva Pharmaceutical Industries Limited , Teva Pharmaceuticals USA, Inc., Teva Finance Services B.V., Teva Finance Services II B.V., Teva Capital Services Switzerland GMBH, Citibank N.A., as administrative agent and HSBC Bank PLC, as documentation agent, dated December 18, 2012 (as amended from time to time)

Senior Unsecured Japanese Yen Term Loan Agreement among Teva Pharmaceutical Industries Limited, Teva Holdings K.K. and Mizuho Bank, Ltd., as administrative agent, dated December 17, 2013

Senior Unsecured Fixed Rate Japanese Yen Term Loan Credit Agreement dated among Teva Pharmaceutical Industries Limited, Teva Holdings G.K. and Sumitomo Mitsui Banking Corporation, as administrative agent, dated March 28, 2012

**Schedule 5.7**  
**Absence of Certain Changes or Events**

Teva's proposal to acquire Mylan N.V.

Dividends declared by Tiger since December 31, 2014:

- \$00.34 per ordinary share – Declared February 5, 2015
- \$00.34 per ordinary share – Declared May 4, 2015

**Schedule 5.9**  
**Consents and Governmental Approvals**

Filings under the Foreign Antitrust Laws whose Consent is required include:

- Canada (clearance)
- The European Union (clearance)
- The Russian Federation (clearance)
- The Republic of Serbia (clearance)
- The Republic of Turkey (clearance)
- Ukraine (clearance)

**Schedule 6.1(b) – Conduct of the Business**

- Pursuant to the sale and purchase agreement entered into on 23 January 2015 between, inter alia, Amit Patel, Meeta Patel and Actavis plc, the determination of the completion statements is still ongoing. The parties are not currently in dispute and Seller Parent's current estimate is that the Vendors (as defined in the purchase agreement) will be entitled to an additional payment of approximately £2.4 million. These discussion with continue following signing of the Agreement.
- An amended version of the Master Supply Agreement between Watson Laboratories, Inc. and Catalent Pharma Solutions, LLC is expected to be signed shortly after signing the Agreement. The version of the Master Supply Agreement that is executed shortly after signing the Agreement is expected to be substantially similar to the draft that has been provided to Buyer Parent prior to the date of the Agreement.
- Buyer Parent and its Subsidiaries (including the Transferring Group) intends to settle ANDA and/or patent claims related to the following products; provided that notwithstanding anything to the contrary, Seller Parent shall inform Buyer Parent a reasonable period in advance prior of entering into a settlement with respect to the following products:
  - Natazia (Settlement/AG Supply)
  - Staxyn (Settlement/AG Supply of Levitra)
  - Beyaz (Settlement/AG Supply)
  - Safyral (Settlement/AG Supply)
  - Xopenex HFA (Settlement/AG Supply)
  - Letairis
  - Treanda
  - Ampyra
  - Multaq
  - Minivelle
  - Abstral
  - Gilenya
  - Absorica
  - Effient (agreement to be bound)
  - Revlimid
  - Men's & Women's Rogaine
  - Brisdelle
  - Zometa
  - Onglyza
  - Kombiglyze XR
  - Nexium Rx
  - Nexium OTC

**Retention Bonus Plan:** Seller Parent may adopt a cash retention program at one or more of the Transferred Entities for key Business Employees, to be paid after the Closing, with an aggregate

retention pool of up to \$20 million, with the participants and terms to be jointly agreed upon by Seller Parent and Buyer Parent in reasonable consultation.



Nothing in Section 6.1 and 6.2 of the Agreement shall prevent the Seller Parent and its Affiliates from implementing any lease terminations or employee terminations in connection with existing integration plans announced as of the date hereof.

**Schedule 6.1(f)**  
**Dividends**

Quarterly dividends by Buyer Parent in accordance with past practice.









Note: Arrow ApS owns a single share (of 3000) of the Mexican company.  
\*Watson Laboratories, S. de R.L. de C.V.









**Allergan plc and Subsidiaries**  
**At August 2, 2016**  
**Tango US Holdings Inc.**  
**including Forest, Aptalis and Furiex**  
*Prepared by Carina Sinclair, Tax Department*

**Allergan Plc**  
EIN: 98-1114402  
(Ireland)

**Actavis Capital S.à r.l.**  
(EIN: 98-1114526) (Luxembourg)

100%  
**Actavis Finance S.à r.l.**  
(EIN: 98-1132938) (Luxembourg)

100%  
**Actavis W.C. Holding Inc.**  
(EIN: 33-1320991) (Delaware)  
*First shown owned by WC PI*

100%  
**WC Pharmaceuticals I Limited**  
(EIN: 98-0621416) (Gibraltar)

99.999%  
**Actavis Capital S.à r.l. Swiss Branch**  
(EIN: 98-1117803) (Luxembourg) May 28, 2014  
*\*\* 0.0001 % owner by AHS as General Partner*

100%  
**"APII"**  
**Allergan Pharmaceuticals International Ltd.**  
(EIN: 98-0406500) (Ireland)

**Actavis Finance S.à r.l. Co.**  
(EIN: 98-1134200) (Ireland)  
*Deregistered on May 26, 2016*

100%  
**Allergan Pharma Ltd.**  
(EIN: 98-0406500) (Ireland)  
*(EIN: 98-0406500) (Ireland)*

100%  
**Tango US Holdings Inc.**  
(EIN: 47-1224902) (Delaware)


100%  
**Allergan Holdings, Inc.**  
*See page 6*

75%  
**Allergan Saudi Arabia LLC**  
(EIN: 98-0406500) (Ireland)

100%  
**AHI CV HoldCo, LLC**  
(Delaware)

83.3%  
**Forest Laboratories, LLC**  
(EIN: 47-1225585) (Delaware)

100%  
**Forest Laboratories, LLC**  
(EIN: 47-1225585) (Delaware)



Corporation  
Entity treated as a disregarded entity for US tax purposes  
Partnership  
Entity treated as a partnership for US tax purposes  
Entity treated as a corporation for US tax purposes





**Allergan plc and Subsidiaries**  
**At August 2, 2016**  
**Allergan, Inc. and Subsidiaries**  
Carina Sinclair, Tax Department


**Allergan Plc (Ireland)**

**ALLERGAN, INC.**

EIN: 95-1622442 0010  
DI: 02/26/48 Pt: California  
DI: 04/14/77 (Reincorp) Pt: Delaware

**Allergan Holdings, Inc.<sup>1</sup>**

EIN: 74-2726884  
DI: 11/17/94 Pt: Delaware,  
Q: Texas 0180



NO	Topic	Response
43.1	The corporate structure of all Allergan entities (including Allergan Finance, LLC, Allergan plc, and all subsidiaries, parents, predecessors, successors and/or associated entities resulting from any and all mergers over the years) and each such entity's involvement with any opioid products from 1995 to the present, including the identification of all drugs, the entity's role in connection with such drugs, and all opioid management involved.	<p data-bbox="1142 266 1388 293"><b><u>Corporate History</u></b></p> <p data-bbox="600 332 1402 360">See provided graphic laying out Allergan's transactional history.</p> <p data-bbox="1127 399 1402 427"><b><u>Corporate Structure</u></b></p> <p data-bbox="600 466 1766 886">The corporate structure of all the entities identified below is shown in the following corporate organizational charts: 2011-01-05 ALLERGAN_MDL_03367307; 2011-01-21 ALLERGAN_MDL_03367302; 2012-10-12 ALLERGAN_MDL_03367301; 2012-11-30 ALLERGAN_MDL_02761472; 2012-12-31 ALLERGAN_MDL_03367304; 2013-01-24 ALLERGAN_MDL_02758853; 2013-06-30 ALLERGAN_MDL_02931208; 2013-10-01 ALLERGAN_MDL_01098786; 2014-01-31 ALLERGAN_MDL_01384578; 2014-06-30 ALLERGAN_MDL_03295845; 2014-12-31 ALLERGAN_MDL_02177059; 2015-01-01 ALLERGAN_MDL_02079795; 2015-09-08 ALLERGAN_MDL_01471538; 2015-09-30 ALLERGAN_MDL_02147315; 2016-01-01 ALLERGAN_MDL_01373731; 2016-03-31 ALLERGAN_MDL_02147111; 2016-08-03 ALLERGAN_MDL_03295865; 2016-09-30 ALLERGAN_MDL_03295869; 2017-06-30 ALLERGAN_MDL_00000006; 2017-08-01 ALLERGAN_MDL_00000001; 2018-03-31 ALLERGAN_MDL_03295860.</p> <p data-bbox="600 925 1297 953">Key Chart - 08-02-2016 ALLERGAN_MDL_03674501</p> <p data-bbox="1094 992 1436 1019"><b><u>Involvement with Opioids</u></b></p> <p data-bbox="600 1058 1077 1086"><b>Transferred Entities/IP Ownership:</b></p> <p data-bbox="600 1125 1906 1260">Allergan sold its generic businesses to Teva in 2016. Teva - Allergan MPA (ALLERGAN_MDL_01481207). As part of that transaction, Allergan sold a number of entities to Teva that were involved with generic opioids. The following entities sold to Teva were listed as the ANDA or NDA holders for the following schedule II opioid products (see FDA "Orange Book"):</p> <ol data-bbox="701 1299 1110 1326" style="list-style-type: none"> <li>1. Watson Laboratories, Inc.</li> </ol>

NO	Topic	Response
		<p>(a) Fentanyl citrate injection (ANDA # 074917)</p> <p>(b) Fentanyl citrate table (ANDA # 079075)</p> <p>(c) Fentanyl transdermal (ANDA # 076709)</p> <p>(d) Hydrocodone / acetaminophen (ANDA #s 081083; 081080; 081079; 040094; 040122; 040123; 040099; 040148; 089883; 040248)</p> <p>(e) Meperidine Hydrochloride Injection (ANDA #s 073443; 073444; 073445)</p> <p>(f) Meperidine Hydrochloride Tablet (ANDA #s 040186)</p> <p>(g) Morphine sulfate injection (ANDA #s 073373; 073374; 073375; 073376)</p> <p>(h) Morphine sulfate capsule (ANDA #s 200812)</p> <p>(i) Oxycodone / acetaminophen (ANDA #s 040234; 040171; 040371; 040535)</p> <p>(j) Oxycodone / aspirin (ANDA #s 040255; 090084)</p> <p>(k) Oxycodone / ibuprofen (ANDA # 078394)</p> <p>(l) Morphine sulfate tablet (ANDA # 075656)</p> <p>2. Actavis Laboratories FL, Inc. f/k/a Watson Laboratories, Inc. - Florida</p> <p>(a) Hydrocodone / acetaminophen (ANDA #s 040493; 040494; 040495; 040148<sup>1</sup>; 206470)</p> <p>(b) Hydrocodone / ibuprofen (ANDA #s 077454; 076604)</p>

<sup>1</sup> Some products are listed under more than one entity if the ANDA or NDA transferred between the entities.



NO	Topic	Response
		<p>(c) Oxycodone / aspirin (ANDA # 090084)</p> <p>(d) Hydromorphone tablet (ANDA # 202144)</p> <p>3. Actavis Totowa LLC</p> <p>(a) Oxycodone / acetaminophen (ANDA #s 040203; 040199; 040800)</p> <p>(b) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 040295)</p> <p>(c) Oxycodone / hydrochloride tablet (ANDA # 076636)</p> <p>4. Actavis Elizabeth LLC</p> <p>(a) Oxycodone / acetaminophen (ANDA #s 040203; 040199; 040800; 201447)</p> <p>(b) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 040295)</p> <p>(c) Morphine sulfate capsule (ANDA #s 020616; 079040)</p> <p>(d) Morphine sulfate tablet (ANDA # 203849)</p> <p>(e) Oxycodone / hydrochloride tablet (ANDA # 076636)</p> <p>(f) Oxycodone / ibuprofen (ANDA # 078769)</p> <p>(g) Oxymorphone tablet (ANDA # 079046)</p> <p>5. Actavis Mid Atlantic LLC</p> <p>(a) Homatropine methylbromide / hydrocodone bitartrate (ANDA # 088017)</p> <p>6. Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc. Salt Lake City</p>

NO	Topic	Response
		<p>(a) Morphine sulfate capsule (NDA # 020616)</p> <p>7. Actavis South Atlantic LLC</p> <p>(a) Oxymorphone tablet (ANDA # 079046)</p> <p>(b) Fentanyl transdermal (ANDA # 077602)</p> <p><b>Remaining Allergan Entities:</b></p> <p><u>Kadian®</u>: From December 19, 2005, until it purchased the medication, Actavis Elizabeth LLC served as the contract manufacturer of Kadian® for Alpharma. February 2, 2008 Actavis Elizabeth and Alpharma Contract (ALLERGAN_MDL_01076982); December 19, 2005, Alpharma - Purepac Contract (ALLERGAN_MDL_01474803).</p> <p>Actavis Elizabeth LLC acquired Kadian® from Alpharma in December 2008. December 17, 2008 Asset Purchase Agreement by and between King Pharmaceuticals, Inc. and Actavis Elizabeth, L.L.C. (ALLERGAN_MDL_01514893).</p> <p>The holders of the Kadian® NDA (020616) since December 2008 were and are (see FDA “Orange Book”):</p> <ul style="list-style-type: none"> <li>December 2008-2013: Actavis Elizabeth LLC</li> <li>2013-2016: Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc. - Salt Lake City</li> <li>2016-Present: Allergan Sales, LLC</li> </ul> <p>April 11, 2013 Transfer Letter (ALLERGAN_MDL_00811313); November 20, 2014, Company Name Change Letter (ALLERGAN_MDL_02195036); March 11, 2016 Transfer Letter (ALLERGAN_MDL_02197647).</p>

NO	Topic	Response
		<p>As part of the sale of its generic business to Teva, Teva agreed to continue manufacturing Kadian® and Norco for Allergan. Exhibit B of Teva-Allergan 2015 MPA (ALLERGAN_MDL_03367042). At that time, Allergan also contracted with UPS SCS, Inc. to distribute controlled substances, including Kadian® and Norco. 2015 UPS Allergan Contract ALLERGAN_MDL_01396729.</p> <p>Since December 2008, Kadian’s label has identified the following entities as the manufacturer or distributor of Kadian®: Actavis Elizabeth LLC; Actavis Kadian LLC; Actavis Pharma, Inc.; and Allergan USA, Inc. 02/2009 Label (ALLERGAN_MDL_02200691); 02/2010 Label (ALLERGAN_MDL_01132982); 07/2012 Label<sup>2</sup>; 04/2014 Label<sup>3</sup>.</p> <p>The current label (revised 09/2018<sup>4</sup>) states that Kadian® is distributed by Allergan USA, Inc.; however, Allergan USA, Inc. does not distribute Kadian® itself. Instead, after Allergan sold the entities with the DEA-registrations required to produce and distribute schedule II controlled substances, Allergan USA, Inc. has contracted with UPS SCS, Inc. to distribute Kadian® on its behalf. 2015 UPS Allergan Contract (ALLERGAN_MDL_01396729).</p> <p><u>Norco</u>: The holders of the Norco ANDAs (40099 &amp; 40148) were and are (<i>see</i> FDA “Orange Book”):</p> <p>ANDA 40099:</p> <ul style="list-style-type: none"> <li>• 1997-1999: UCB Pharmaceuticals, Inc.</li> <li>• 2000-2015: Watson Laboratories, Inc.</li> <li>• 2016: Allergan Sales, LLC</li> <li>• 2017-Present: Allergan Pharmaceuticals International Limited</li> </ul>

<sup>2</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/020616s041lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020616s041lbl.pdf)

<sup>3</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/020616s051lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020616s051lbl.pdf)

<sup>4</sup> [https://www.allergan.com/assets/pdf/kadian\\_pi](https://www.allergan.com/assets/pdf/kadian_pi)

NO	Topic	Response
		<p>ANDA 40148:</p> <ul style="list-style-type: none"> <li>• 1997-2014: Watson Laboratories, Inc.</li> <li>• 2015: Actavis Laboratories FL, Inc.</li> <li>• 2016: Allergan Sales, LLC</li> <li>• 2017-Present: Allergan Pharmaceuticals International Limited</li> </ul> <p>The following entities were involved in manufacturing and distributing Norco: Watson Pharma, Inc., Watson Laboratories, Inc., Warner Chilcott Company, LLC, Allergan USA, Inc., and Allergan Sales, LLC. 04/2002 Label (ALLERGAN_MDL_01095947); April 2003 Label (ALLERGAN_MDL_01095940); 07/2007 Label (ALLERGAN_MDL_01680965); 10/2009 Label (ALLERGAN_MDL_02206790); 06/2011 Labels (ALLERGAN_MDL_02209823; ALLERGAN_MDL_02210219); 08/2012 Label (ALLERGAN_MDL_01768757); 08/2013 Labels (ALLERGAN_MDL_02210402; ALLERGAN_MDL_02209867); 2014 Labels<sup>5</sup>; 02/2017 Label (ALLERGAN_MDL_02219168); Current Label<sup>6</sup>.</p> <p>Similar to Kadian®, after Allergan sold the entities with the DEA-registrations required to produce and distribute schedule II controlled substances, Allergan contracted with Teva and UPS, SCS Inc. to manufacture and distribute Norco on behalf of Allergan USA, Inc. and Allergan Sales, LLC. 2015 UPS Allergan Contract (ALLERGAN_MDL_01396729); Exhibit B of Teva-Allergan 2015 MPA (ALLERGAN_MDL_03367042).</p> <p><u>Other Schedule II Branded Drugs:</u> Between 2004 and 2006, Watson Pharmaceuticals, Inc., collaborated with Interpham, Inc. (the ANDA holder) in the marketing and sale of Reprexain (ANDA 076642 - Hydrocodone bitartrate / ibuprofen). June 07, 2004 Email &amp; Press Release Announcing Launch</p>

<sup>5</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/040099Orig1s0181bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040099Orig1s0181bl.pdf);

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/040148s0531bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040148s0531bl.pdf)

<sup>6</sup> [https://www.allergan.com/assets/pdf/norco\\_pi](https://www.allergan.com/assets/pdf/norco_pi)

NO	Topic	Response
		<p>(ALLERGAN_MDL_01830938; ALLERGAN_MDL_01830941); June 14, 2006 Email Discussing No Longer Promoting Reprexain (ALLERGAN_MDL_01728789).</p> <p>On October 12, 2000, Watson Pharma, Inc. announced the addition of Maxidone (40094 - hydrocodone bitartrate / acetaminophen) to its product portfolio. October 12, 2000 Product Introduction Notification (ALLERGAN_MDL_02579713). Since 2015, Maxidone has been included on the FDA's list of discontinued drugs. (See 2015 FDA Orange Book, "Discontinued Drug Product List").</p> <p>Actavis acquired Forest Laboratories, Inc. in 2014. Prior to the acquisition, Forest Laboratories, Inc. sold a product called Combunox (021378 - Oxycodone Hydrochloride / ibuprofen). Forest received approval for Combunox on November 26, 2004. Since 2012, Combunox has been included on the FDA's list of discontinued drugs. (See 2012 FDA Orange Book, "Discontinued Drug Product List").</p>
43.2	<p>The management of the generic opioid business from 1995 to the present for all Allergan entities (including Allergan Finance, LLC, Allergan plc, and all subsidiaries, parents, predecessors, successors and/or associated entities resulting from any and all mergers over the years) and all generic opioids for which any Allergan entities had any involvement</p>	<p>Each of the seven entities identified above that had involvement with generic opioid medications is included on Schedule 4.6(g) of the Teva-Allergan MPA, which lists the entities transferred to Teva. Teva-Allergan MPA Schedules (ALLERGAN_MDL_03367048).</p> <p>The January 1, 2015, organization chart shows where each of these entities fell within the the corporate structure of Allergan prior to the sale to Teva. ALLERGAN_MDL_02079795. Actavis South Atlantic LLC, Actavis Elizabeth, LLC, Actavis Mid Atlantic LLC, and Actavis Totowa LLC were all direct subsidiaries of Actavis LLC, which was an indirect subsidiary of Watson Laboratories, Inc. <i>See id</i> at 2. Watson Laboratories, Inc. was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>See id</i>. Actavis Laboratories UT, Inc. was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>Id</i>. Actavis Laboratories FL, Inc. (f/k/a Watson Laboratories, Inc. - Florida) was a direct subsidiary of Andrx Corporation, which was a direct subsidiary of Actavis, Inc. n/k/a Allergan Finance, LLC. <i>Id</i>. Andrx Corporation and Actavis LLC, in addition to the seven generic ANDA-holding entities, were transferred to Teva. Teva-Allergan MPA Schedules (ALLERGAN_MDL_03367048).</p> <p>Prior to the sale of these entities to Teva, Actavis, Inc. n/k/a Allergan Finance, LLC did not manufacture, market, distribute, or sell any pharmaceutical products. It operated solely as a holding company. All of the direct subsidiaries of Actavis, Inc. n/k/a Allergan Finance involved in the management of the generic</p>

NO	Topic	Response
		<p>opioid business were transferred to Teva. No other affiliate of Allergan Finance LLC or Allergan plc had involvement with generic opioids.</p> <p><u>Officers &amp; Directors of Generic Entities:</u></p> <p>Based on a review of reasonably available documents, we have identified the following persons as directors and officers of some of the entities identified above.</p> <p><b><u>Watson Pharma, Inc.</u></b></p> <p><u>7-24-2012:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Ranjana B. Pathak, Andrew Boyer, Charles M. Mayr, Lynne Amato, Thomas R. Griffin, Tim Callahan, Diane Miranda, Kathleen Reape, Allan Slavsky, Michael W. Carr, Sigurd C. Kirk, James O'Brien, James A. Williamson, Brett W. Hagardorn.</p> <p><i>See ALLERGAN_MDL_03367292</i></p> <p><u>8-30-2013:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Ranjana B. Pathak, Andrew Boyer, Charles M. Mayr, Lynne Amato, Thomas R. Griffin, Tim Callahan, Kathleen Reape, Allan Slavsky, Michael W. Carr, Sigurd C. Kirk, James O'Brien, James A. Williamson, Brett W. Hagardorn, John Larocca.</p> <p><i>See ALLERGAN_MDL_03367295.</i></p> <p><b><u>Watson Laboratories, Inc.</u></b></p>

NO	Topic	Response
		<p><u>7-24-2012:</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Patrick G. Brunner, Charles D. Ebert, Ranjana B. Pathak, Nick Kerkhof, Gary Kozloski, Gary Holloway, Jeffery Regan, Beth Brennan, Kathleen Reape, Michael W. Carr, James O'Brien, James A. Williamson, Miguel A. Gomez, Brett W. Hagadorn, Roberta Loomar.</p> <p><i>See</i> ALLERGAN_MDL_03367294.</p> <p><u>8-30-2013</u></p> <p>Director: Paul M. Bisaro;</p> <p>Officers: Paul M. Bisaro, G. Frederick Wilkinson, Robert A. Stewart, R. Todd Joyce, David A. Buchen, Patrick G. Brunner, Charles D. Ebert, Ranjana B. Pathak, Hafrun Fridriksdottir, Nick Kerkhof, Gary Kozloski, Gary Holloway, Jeffery Regan, Beth Brennan, Kathleen Reape, Michael W. Carr, James O'Brien, James A. Williamson, Miguel A. Gomez, Brett W. Hagadorn, John Larocca.</p> <p><i>See</i> ALLERGAN_MDL_03367296.</p>
43.3	All involvement and communications Allergan plc has had with any of its subsidiaries involved in the licensing, manufacture, marketing, sale, or distribution of any opioid products, including Allergan plc's ownership interests in, control over, and financial interrelationships with any	<p>Allergan plc "was established for the purpose of facilitating the business combination between Allergan Finance, LLC (formerly known as Actavis, Inc.) and Warner Chilcott plc." Allergan plc 2017 10-K at 3. Allergan Finance, LLC acquired Warner Chilcott plc in a stock-for-stock transaction in 2013. 5/19/2013 Actavis, Inc. 8-K at 9. After the transaction, Warner Chilcott and Allergan Finance, LLC each became wholly owned, indirect subsidiaries of Allergan plc. Allergan plc 2017 10-K at 3.</p> <p>Allergan plc f/k/a Actavis plc is an Irish corporation and its only offices are located in Ireland. Allergan plc is a holding company that exists for the purpose of holding shares of other companies that manufacture and distribute prescription drugs rather than producing or selling its own goods or services. Allergan plc does not finance or control the daily affairs, including marketing or sales operations, of its subsidiaries.</p>



NO	Topic	Response
	such subsidiaries, as well as how subsidiaries' management interacted with and reported to Allergan plc and how this changed over time.	<p>The following individuals are or were the primary executives at Allergan Finance, LLC in the following categories at the specified time period:</p> <p><b><u>Watson Pharmaceuticals, Inc.</u></b></p> <p><u>Officers</u></p> <ul style="list-style-type: none"> <li>(i) Chief Executive Officer: Allen Chao (1999-2008), Paul Bisaro (2008-2012)</li> <li>(ii) Chief Financial Officer: Michael Boxer (1999-2002), Charles Slacik (2003-2007), Mark Durand (2008-2009), R. Todd Joyce (2010-2012)</li> <li>(iii) Chief Operating Officer: Fred Wilkinson (1999-2000), Joseph Papa (2001-2004), Robert Stewart (2010-2012)</li> <li>(iv) General Counsel: Robert Funsten (1999-2001), David Buchen (2002-2012)</li> <li>(v) Sales: Lynne Amato (1999, 2003-2009), Carolyn Logan (1999), Andy Boyer (2003-2012), Tim Callahan (2010-2012)</li> <li>(vi) Marketing: Lynne Amato (1999, 2003-2012), Carolyn Logan (1999), Andy Boyer (2003-2012)</li> <li>(vii) Compliance: Roberta Loomar (2008-2010), Deborah Penza (2011-2012)</li> <li>(viii) Sales or Marketing Training: None</li> <li>(ix) Government Affairs: G. Thomas Long (2004-2010), Charlie Mayr (2011-2012)</li> <li>(x) Medical Director: Gary Kozloski (2001-2012)</li> <li>(xi) Research and Development: Charles Ebert (1999-2012), Francois Menard (2007-2012)</li> </ul> <p><u>Directors</u></p> <ul style="list-style-type: none"> <li>(i) Paul Bisaro (2007 - 2012)</li> <li>(ii) Christopher Bodine (2009 - 2012)</li> <li>(iii) Allen Chao (1983 - 2009)</li> <li>(iv) Michael Fedida (1995 - 2012)</li> <li>(v) Michael Feldman (1985 - 2012)</li> <li>(vi) Albert Hummel (1986 - 2012)</li> <li>(vii) Alec Keith (1991 - 2000)</li> <li>(viii) Catherine Klema (2004 - 2012)</li> <li>(ix) Jack Michelson (2002 - 2012)</li> </ul>

NO	Topic	Response
		<p>(x) Melvin Sharoky (1995 - 1998)</p> <p>(xi) Anthony Tabatznik (2009 - 2012)</p> <p>(xii) Ronald Taylor (1994 - 2012)</p> <p>(xiii) Andrew Turner (1997 - 2012)</p> <p>(xiv) Fred Weiss (2000 - 2012)</p> <p><b><u>Actavis, Inc.</u></b></p> <p><b><u>Officers:</u></b></p> <p>(i) Chief Executive Officer: Paul Bisaro (2013-2014), Brent Saunders (2015-2016)</p> <p>(ii) Chief Financial Officer: Todd Joyce (2013-2014), Tessa Hilado (2015-2016)</p> <p>(iii) Chief Operating Officer: Robert Stewart (2013-2016)</p> <p>(iv) General Counsel: David Buchen (2013-2014), A. Robert D. Bailey (2015-2016)</p> <p>(v) Sales: Andy Boyer (2013), Tim Callahan (2013), Siggi Olafsson (2013-2014), William Meury (2015-2016)</p> <p>(vi) Marketing: Andy Boyer (2013), Lynne Amato (2013), Siggi Olafsson (2013-2014), William Meury (2015-2016)</p> <p>(vii) Compliance: Debra Penza (2013-2014), Joseph Zimmerman (2014), Jonathon Kellerman (2015-2016)</p> <p>(viii) Sales or Marketing Training: None</p> <p>(ix) Government Affairs: Charlie Mayr (2013-2014), Alex Kelly (2015-2016)</p> <p>(x) Medical Director: Gary Kozlowski (2013), Gavin Corcoran (2014-2016)</p> <p>(xi) Research and Development: Chuck Ebert (2013-2014), Hafrun Fridriksdottir (2013-2014), David Nicholson (2015-2016)</p> <p><b><u>Directors</u></b></p> <p>(i) Paul Bisaro (2013-2014)</p> <p>(ii) Christopher Bodine (2013-2014)</p> <p>(iii) Michael Fedida (2013-2014)</p> <p>(iv) Michael Feldman (2013-2014)</p> <p>(v) Albert Hummel (2013-2014)</p> <p>(vi) Catherine Klema (2013-2014)</p>

NO	Topic	Response
		<p>(vii) Jack Michelson (2013-2014)</p> <p>(viii) Ronald Taylor (2013-2014)</p> <p>(ix) Andrew Turner (2013-2014)</p> <p>(x) Fred Weiss (2013-2014)</p> <p><b><u>Allergan Finance, LLC</u></b></p> <p><b><u>Officers</u></b></p> <p>Allergan Finance, LLC's management structure is set forth in the Second Amended and Restated Operating Agreement of Allergan Finance, LLC (ALLERGAN_MDL_SUPP_00000326). This Operating Agreement identifies the following officers:</p> <p>(i) A. Robert D. Bailey</p> <p>(ii) Matthew M. Walsh</p> <p>(iii) Jonathon Kellerman</p> <p>(iv) Karen Ling</p> <p>(v) Alex Kelly</p> <p>(vi) William Meury</p> <p>(vii) Sigurd Kirk</p> <p>(viii) Marc Princen</p> <p>(ix) James D'Arecca</p> <p>(x) Sean Lennon</p> <p>(xi) David Nicholson</p> <p>(xii) Lynne Bolduc</p> <p>(xiii) Thomas Poche</p> <p>(xiv) Brian Anderson</p> <p>(xv) Riccardo Mancuso</p> <p>(xvi) Martin Shindler</p> <p>(xvii) Wayne Swanton</p> <p>(xviii) Stephen M. Kaufhold</p> <p>(xix) Kira Schwartz</p> <p>(xx) Judith Tomkins</p>

NO	Topic	Response
		<p><u>Directors</u> Allergan Finance, LLC does not have a Board of Directors. Allergan Finance, LLC instead has a two-person Board of Managers that is comprised of A. Robert D. Bailey and Matthew M. Walsh.</p> <p><b><u>Allergan plc Board &amp; Executive Leadership Team:</u></b></p> <p><b>10-02-2013<sup>7</sup></b></p> <p><u>Directors:</u></p> <ul style="list-style-type: none"> <li>(i) Paul M. Bisaro</li> <li>(ii) James H. Bloem</li> <li>(iii) Christopher Bodine</li> <li>(iv) Tamar D. Howson</li> <li>(v) John A. King</li> <li>(vi) Catherine M. Klema</li> <li>(vii) Jiri Michal</li> <li>(viii) Jack Michelson</li> <li>(ix) Sigurdur Oli Olafsson</li> <li>(x) Patrick J. O'Sullivan</li> <li>(xi) Andrew L. Turner</li> <li>(xii) Fred G. Weiss</li> </ul> <p><b>Current Leadership:</b></p> <p><u>Executive Leadership Team:</u></p> <ul style="list-style-type: none"> <li>(i) Brenton L. Saunders, Chairman, President and CEO</li> <li>(ii) William Meury, EVP &amp; Chief Commercial Officer</li> <li>(iii) Matt Walsh, EVP &amp; Chief Financial Officer</li> <li>(iv) A. Robert D. Bailey, EVP &amp; Chief Legal Officer and Corporate Secretary</li> <li>(v) Karen L. Ling, Esq., EVP &amp; Chief Human Resources Officer</li> </ul>

<sup>7</sup> <https://www.allergan.com/news/news/thomson-reuters/actavis-plc-names-board-of-directors>

NO	Topic	Response
		<p>(vi) C. David Nicholson, PhD, EVP &amp; Chief R&amp;D Officer</p> <p>(vii) Alex Kelly, EVP &amp; Chief Communications Officer</p> <p>(viii) Wayne R. Swanton, EVP, Global Operations</p> <p><u>Directors</u></p> <p>(i) Nesli Basgoz, M.D.</p> <p>(ii) Joseph H. Boccuzi</p> <p>(iii) Christopher W. Bodine</p> <p>(iv) Adriane M. Brown</p> <p>(v) Christopher J. Coughlin</p> <p>(vi) Carol Anthony (John) Davidson</p> <p>(vii) Michael E. Greenberg, PhD</p> <p>(viii) Thomas C. Freyman</p> <p>(ix) Catherine M. Klema</p> <p>(x) Peter J. McDonnell, M.D.</p> <p>(xi) Fred G. Weiss</p>